



(11) Publication number : **0 502 637 A2**

(12)

EUROPEAN PATENT APPLICATION

(21) Application number : **92301465.8**

(51) Int. Cl.⁵ : **C12N 15/63, C12N 15/68,
C07K 15/00**

(22) Date of filing : **21.02.92**

(30) Priority : **26.02.91 GB 9104017**
29.04.91 GB 9109188

(43) Date of publication of application :
09.09.92 Bulletin 92/37

(84) Designated Contracting States :
**AT BE CH DE DK ES FR GB GR IT LI LU MC NL
PT SE**

(71) Applicant : **IMPERIAL CHEMICAL
INDUSTRIES PLC**
Imperial Chemical House, Millbank
London SW1P 3JF (GB)

(72) Inventor : **Barth, Peter Thomas**
Alderley Park
Macclesfield, Cheshire SK10 4TG (GB)

(74) Representative : **Bill, Kevin et al**
ICI Group Legal Dept: Patents, P.O. Box 6,
Shire Park, Bessemer Road
Welwyn Garden City, Hertfordshire AL7 1HD
(GB)

(54) **Vector.**

(57) The invention relates to vectors which include an inducible selection gene and a sequence which codes for a heterologous polypeptide. In a particular example the selection gene comprises the tetA and tetR genes. The vector may also include a sequence which is capable of conferring stability on the vector, such as the cer sequence, a transcription terminator, such as gene 32 from bacteriophage T4, a ribosome binding site, and a multi-cloning site. Hosts transformed with the vector, processes for preparing these hosts, and processes for preparing polypeptides using these hosts.

EP 0 502 637 A2

The present invention relates to a vector which includes an inducible selection gene, a host containing the vector and processes for preparing the vector and host.

The majority of bacterial cloning and expression vectors contain an antibiotic resistance marker as a simple means to maintain selection for the plasmid in the bacterial host of choice. This is commonly ampicillin because of the fact that one of the original cloning vectors constructed, pBR322, carries an ampicillin resistance determinant (Bolivar *et al*, 1977, *Gene* 2: 95-113). One of the derivatives of this plasmid is pAT153 (Twigg and Sherratt, 1980, *Nature* 283: 216-218). The ampicillin resistance marker is constitutively controlled as are the majority of plasmid encoded resistances.

Although a number of selection systems have been used in cloning vectors for the preparation of polypeptides, there is still a need for improved selection systems.

According to the present invention there is provided a vector which comprises an inducible selection gene, and a sequence which codes for a heterologous polypeptide.

The term "vector" as used herein is used in its broadest sense and includes within its meaning any replicon capable of transferring recombinant DNA material from one cell to another. The present invention includes vectors suitable for integration into a host, and vectors, such as plasmids, which are useful in constructing vectors for transfer of recombinant DNA to hosts.

The inducible "selection gene" (or selection marker) will, in general, include a gene which facilitates selection and is inducible. The inducible selection gene may comprise a first gene which codes for a substance which facilitates selection, and a second gene which controls expression of that substance so that expression only occurs under defined conditions. Thus, for example the first gene may comprise a gene which codes for a substance which confers resistance to an antibiotic and the second gene may comprise a gene which codes for a repressor. In the presence of the antibiotic the system is induced and expression of the first gene takes place to confer antibiotic resistance, thus permitting recombinant vectors which carry the selection gene to be selected. In the absence of the antibiotic, repression occurs so that expression of the first gene does not take place and the substance which confers antibiotic resistance in the vector is not produced.

A particular example of a suitable inducible selection gene is one which includes the *tetA* and *tetR* genes. The *tetA* gene is the gene which codes for a substance which confers resistance to tetracycline; whilst the *tetR* gene codes for a repressor protein which is able to prevent expression of the *tetA* gene. The system is induced in the presence of tetracycline, so that in its presence the *tetA* gene is expressed thus conferring tetracycline resistance on the vectors which carry the selection gene. In the absence of tetracycline, the *tetA* gene is repressed by the *tetR* gene so that expression of *tetA* does not take place and the product of this gene is not generated.

Thus in particular embodiment of the present invention there is provided a vector which comprises an inducible selection gene which comprises the *tetA* and *tetR* genes, and a sequence which codes for a heterologous polypeptide.

The vector may, in addition to the sequences mentioned above include other DNA sequences suitable for particular applications, such as appropriate control sequences. For example the vector may include a promoter, ribosome binding site and transcription terminator sequence. The vector will, in general, include an origin of replication, for example that derived from plasmid pAT153.

A particular example of a suitable promoter is the tryptophan (*trp*) promoter. Other promoters may be used. For example, in a further embodiment of the present invention the vector includes the T7A3 promoter (SEQ ID NO 42), in which case the vector may optionally also include an operator such as *lacO* (especially the shortened *lacO* sequence of SEQ ID NO 43). The T7A3 promoter sequence shown in SEQ ID NO 42 is shown up to the base before the beginning of mRNA, so that when used with the *lacO* sequence the *lacO* sequence of SEQ ID NO 43 extends from +1 (beginning of mRNA).

A particular example of a transcription terminator is a derivative of the transcription terminator sequence found in bacteriophage T4 gene 32.

A sequence which confers stability on the vector may also be present. An example of such a sequence is the *cer* sequence (see, for example, Cell, 36, 1097-1103, 1984).

The vector may include a multicloning sequence to facilitate the introduction of ribosome binding sequences, and genes for heterologous polypeptides etc.

The heterologous polypeptide may comprise a polypeptide which possesses pharmacological properties, and is hence of use in medicine. A particular example of such a polypeptide is ricin A which may be used in the preparation of immunotoxins. A further example is a polypeptide known as G-CSF or an analogue thereof.

Granulocyte colony stimulating factor (G-CSF) has been described in the literature by Wallet K. *et al* Proc. Natl. Acad. Sci. USA Vol 82, pp 1526-1530 and has also been described in European Patent Publication No 169,566 and PCT Patent Publication No W0 87/01132. G-CSF has been shown to stimulate granulocyte production *in vivo* and to function with minimal side effects. As a result human G-CSF is seen as having potential

utility in the management of neutropaenia associated with chemotherapy, radiation therapy, radiation accident or autologous bone marrow transplantation. Moreover G-CSF may have utility in the stimulation of bone marrow suppression associated with AIDS, in the treatment of myelodysplastic syndromes characterised by granulocyte functional abnormalities and as an adjunct to the treatment of severe infections.

5 The term "human G-CSF" as used herein refers to those G-CSFs that have been found to exist in nature and includes the two polypeptides having the amino acid sequence set out in SEQ. ID No 41. These two polypeptides differ only in so far as a tripeptide insert Val-Ser-Glu is present in one polypeptide between positions 35 and 36, but absent in the other. The numbering used throughout the present specification is based on the naturally occurring polypeptide without the Val-Ser-Glu insert.

10 Analogues of G-CSF include polypeptides which differ from that of naturally occurring G-CSFs in terms of the identity or location of one or more amino acid residues. For example, such analogues may contain substitutions, or terminal or intermediate additions or deletions of such residues. Such analogues would share the property of natural G-CSFs of being able to stimulate granulocyte production.

15 In particular the present invention provides a replicable expression vehicle which comprises a vector as hereinbefore defined.

In a particular embodiment of the present invention there is provided a replicable plasmidic expression vehicle which comprises an inducible selection gene comprising the tetA and tetR genes, and a DNA sequence which codes for a heterologous polypeptide.

20 As indicated above, the expression vehicle may include a sequence capable of conferring stability on the expression vehicle, such as the cer sequence.

In a further embodiment of the present invention there is provided a vector which comprises a replicable plasmidic expression vehicle comprising a promoter, the cer sequence, a transcription terminator as found in the terminus of gene 32 bacteriophage T4, an origin of replication and a DNA sequence which codes for a heterologous polypeptide.

25 According to the present invention there is also provided a process for preparing a polypeptide, said process comprising culturing a host which comprises a vector of the present invention so that the polypeptide is expressed.

30 The process may be carried out in the absence of the product used in selection. For example, in the case where the selection system comprises the tetA and tetR genes, the process may be carried out in the absence of tetracycline.

The above-mentioned process may be effected by the use of any appropriate host cell, such as bacterial, yeast, or mammalian cells. A particular example of a suitable host comprises bacterial cells, for example E. coli.

35 It will be appreciated that where the desired metabolite is not passed out of the host at a useful rate, the host may be cultured and harvested as the intact cell and the desired polypeptide recovered by subsequently extracting the cells, for example after separation from the medium containing nutrients necessary for growth of the host cell. Where the metabolite is passed out of the host cell into the surrounding culture solution, then the polypeptide may be recovered by extraction in the normal way.

40 According to the present invention there is also provided a host capable of expressing a heterologous polypeptide, which host comprises a vector (such as replicable plasmidic expression vehicle) as herein defined.

In a particular embodiment of the present invention there is provided a host transformed with a replicable plasmidic expression vehicle which comprises an inducible selection gene comprising the tetA and tetR genes, and a DNA sequence which codes for a heterologous polypeptide.

45 According to a further feature of the present invention there is also provided a process for the preparation of a host as hereinbefore defined, said process comprising transforming a host by the insertion therein of a vector (such as a replicable plasmidic expression vehicle) as hereinbefore defined.

50 Suitable methods for the introduction of foreign genetic material into a host are known from the literature. Such methods include formation of a replicable expression vehicle comprising a vector and the foreign genetic material, and introduction of the vehicle into the host. Introduction of the vehicle into the host may be facilitated by subjecting the host to an appropriate treatment, for example in the case of E. coli, by treatment with calcium chloride solution.

55 The present invention also provides a process for the preparation of a vector as herein defined comprising inserting a sequence which codes for the desired polypeptide into a vector (as herein defined) at an appropriate insertion site so that a vector (conveniently in the form of a replicable plasmidic expression vehicle) is obtained which is capable of directing synthesis of the polypeptide.

According to a further aspect of the present invention there is provided a vector which comprises an inducible selection gene. The selection gene may be as defined hereinbefore, for example it may comprise the tetA and tetR genes.

The vector of the present invention utilises an inducible selection gene. This has been found to be particularly advantageous since the product of this gene (tetA in the preferred embodiment) is only expressed during the construction and testing phases of the genetic manipulation. If the subsequent plasmid carrying the cloned gene is stably maintained in its bacterial host, the need for selection ceases. Cultures grown to express the cloned gene product will therefore not require addition of the selection drug and will consequently not express the product of the selection gene. Such a product is unavoidable in most vectors because they carry constitutively expressed selection genes. Such unwanted products are disadvantageous because they divert metabolic energy away from the cloned gene product and may produce undesirable contaminants. In particular the vectors of the present invention avoids the use of penicillins as selection markers. This is particularly advantageous because of the prevalence of allergic reactions to penicillin or its breakdown products in human populations. Presence of a β -lactamase encoded by the plasmid would prevent the simple detection of any such contaminating β -lactams as active antibiotics.

The use of the tetA/tetR genes as a selection system has been found to particularly advantageous as, in general, the vectors which contain this selection system are unexpectedly stable. This stability helps to maintain expression levels and to improved accumulation of polypeptides, such as ricin A.

The stability of the vectors of the present invention is exemplified by pICI0042 which carries the tetA/tetR selection gene. This plasmid was unexpectedly found to have gained stability over its parent pAT153, even without the presence of the cer sequence. This is an unexpected but very welcome advantage of the construction of this plasmid.

The invention will now be further described, by way of example only, with reference to the following Examples; and accompanying drawings in which:

Figure 1 illustrates transcription terminator sequences;

Figure 2 illustrates the preparation of pTB344;

Figure 3 illustrates the preparation of pICI0042;

Figure 4 is a plasmid map of pICI0042;

Figure 5 describes fragments used in the preparation of plasmids;

Figure 6 is a plasmid map of pICI1079;

Figure 7 is a plasmid map of pLB015;

Figure 8 is a plasmid map of pCGG1;

Figure 9 describes the sequence of [Ser^{17,27}]G-CSF;

Figure 10 describes the sequence of h-GCSF;

Figure 11 is a plasmid map of pCG54;

Figure 12 illustrates the construction of pICI0020;

Figure 13 illustrates the construction of pICI1078;

Figure 14 illustrates the construction of pICI1102;

Figure 15 illustrates a coomassie stained SDS gel of E.coli lysates in which track A is pICI1102; B is pICI0020, and C is molecular weight markers.

Figure 16 illustrates a gel profile of pICI1102 in which peak R represents ricin A;

Figure 17 is a western blot of ricin A produced by pICI1102 and in which track 1 is molecular weight markers; 2 and 3 are non-ricin producing clones; 4 is pICI1102; and 5 is pICI0020 (control plasmid - no ricin A sequence);

Figure 18 is a partial sequence of pICI1102; and

Figure 19 illustrates the construction of pICI1187.

The sequences referred to are set out in the "Sequence Listing" following the Examples and sequences are specified in the conventional 5' to 3' sense.

BUFFERS FOR RESTRICTION ENZYMES

Stability: stable at -20°C.

Buffer composition:

| | Buffer components | Final concentration in mmol/l (1:10 diluted set buffer) | | |
|----|------------------------|--|-----|-----|
| | | B | M | H |
| 5 | Tris-HCl | 10 | 10 | 50 |
| | MgCl ₂ | 5 | 10 | 10 |
| | NaCl | 100 | 50 | 100 |
| 10 | Dithioerythritol (DTE) | - | 1 | 1 |
| | 2-Mercaptoethanol | 1 | - | - |
| 15 | pH at 37°C | 8.0 | 7.5 | 7.5 |

The above buffers are available from Boehringer Mannheim.

In the site-directed mutagenesis procedure - Example 7

| | |
|----------|-------------------------|
| Buffer 1 | 100 mM Tris HCl pH 8.0 |
| 20 | 100 mM NaCl |
| | 20 mM MgCl ₂ |
| Buffer 2 | 10 mM Tris HCl pH 8.0 |
| | 20 mM NaCl |
| | 1 mM EDTA |
| 25 | Buffer 3 |
| | 12 mM Tris HCl pH 7.7 |
| | 30 mM NaCl |
| | 10 mM MgCl ₂ |
| | 8 mM 2-mercapto ethanol |
| 30 | Buffer 4 |
| | 60 mM Tris HCl pH 8.0 |
| | 90 mM NaCl |
| | 6 mM MgCl ₂ |
| | 10 mM DTT |

Nucleotide mix 1 250 µM each of dATP, dGTP, dCTP=S (phosphorothioate derivative of dCTP), dTTP and 1 mM ATP

35 Nucleotide mix 2 250 µM each of dATP, dGTP, dCTP, dTTP and 350 µM ATP

M9 minimal media

| | | |
|----|-------------------------------------|------|
| 40 | Ammonium chloride | 1g |
| | Disodium hydrogen orthophosphate | 6g |
| | Potassium dihydrogen orthophosphate | 3g |
| 45 | Sodium chloride | 0.5g |
| | In distilled water | 1 l. |

Supplements/75ml

| | | |
|----|--------|------------------------|
| 50 | 300 µl | 50% glucose |
| | 75 µl | 1M MgSO ₄ |
| | 75 µl | 0.1M CaCl ₂ |
| | 75 µl | 4 mg/ml thiamine |
| 55 | 75 µl | 20% casein amino acids |

Trace Element Solution (TES)

TES has the following composition:-

| | | |
|----|--|-----------------|
| 5 | | mg/10 ml |
| | | deionised water |
| 10 | $\text{AlCl}_3 \cdot 6\text{H}_2\text{O}$ | 2.0 |
| | $\text{CoCl}_2 \cdot 6\text{H}_2\text{O}$ | 0.8 |
| | $\text{KCr}(\text{SO}_4)_2 \cdot 12\text{H}_2\text{O}$ | 0.2 |
| | $\text{CuCl}_2 \cdot 2\text{H}_2\text{O}$ | 0.2 |
| 15 | H_3BO_3 | 0.1 |
| | KI | 2.0 |
| | $\text{MnSO}_4 \cdot \text{H}_2\text{O}$ | 2.0 |
| 20 | $\text{NiSO}_4 \cdot 6\text{H}_2\text{O}$ | 0.09 |
| | $\text{Na}_2\text{MoO}_4 \cdot 2\text{H}_2\text{O}$ | 0.4 |
| | $\text{ZnSO}_4 \cdot 7\text{H}_2\text{O}$ | 0.4 |

25 Geneclean (TM)

The kit contains 1) 6M sodium iodide 2) a concentrated solution of sodium chloride, Tris and EDTA for making a sodium chloride/ethanol/water wash; 3) Glassmilk (TM)- a 1.5 ml vial containing 1.25 ml of a suspension of silica matrix in water.

30 This is a technique for DNA purification based on the method of Vogelstein and Gillespie published in Proceedings of the National Academy of Sciences USA (1979) Vol 76, p 615.

Alternatively any of the methods described in "Molecular Cloning - a laboratory manual" Second Edition, Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989) can be used.

35 Random Label Kit Product of Pharmacia No 27-9250

The procedure is described in "Molecular Cloning - a Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis, pp 10.13-10.17 (Published by Cold Spring Harbor Laboratory 1989).

40 Sequenase (TM)

Chemically modified T7 DNA polymerase

Based on the procedure of Tabor and Richardson published in "Proceedings of the National Academy of Sciences USA (1987) vol 84 pp 4767-4771.

T4 DNA ligase

50 Described in "Molecular Cloning - a Laboratory Manual" Second Edition, Sambrook, Fritsch and Maniatis 5.60-5.64 (Published by Cold Spring Harbor Laboratory 1989) and also by Weiss B. et al J. Biol. Chem. Vol 243 p 4543 (1968).

E.coli strains

55 The E. coli strains HB101 and CGSC 6300 (also referred to herein as MSD522) are freely available. Thus for example they may be obtained from the E. coli Genetic Stock Centre, Yale University, USA. Moreover E. coli HB101 may additionally be obtained from for example BRL supplied by GIBCO Limited Unit 4, Cowley Mill Trading Estate, Longbridge Way, Uxbridge, UB8 2YG, Middlesex, England or GIBCO Laboratories, Life

Technologies Inc., 3175 Staley Road, Grand Island, NY 14072, USA. The genotype of strain HB101 is described in the aforementioned "Molecular Cloning - A Laboratory Manual" as Sup E44 hsd S20 ($r_B^- m_B^-$) rec A 13 ara-14 F⁻leu 6 thi-1 proA2 lac Y1 gal K2 rps L20 xyl⁻5 mtl⁻1. The genotype of MSD 522 (CGSC 6300) is set out in Example 3.

5 The following non-limiting Examples are given by way of illustration only.

EXAMPLE 1

Preparation of plasmids containing trp promoter/tetA/tetR genes.

10

(a) Preparation of pICI0042

Many plasmid vectors are based on one of the original cloning vectors: pBR322 (Bolivar *et al.*, 1977, *Gene* 2: 95-113). The non-mobilizable pAT153 is a derivative of this (Twigg and Sherratt, 1980, *Nature* 283: 216-218).

15

Both these plasmids contain the ampicillin resistance determinant, TEM β -lactamase. Plasmid pICI0042 utilises a repressed tetracycline resistance determinant, as found on the naturally-occurring plasmid RP4. This repressed system shuts off expression of the tetA gene in the absence of tetracycline whereas most drug resistant mechanisms have constitutive expression.

20

The tet locus was first mapped on RP4 by Barth and Grinter (*J. Mol. Biol.* 113: 455-474, 1977). This was shown to consist of adjacent genes: tetA, the structural resistance gene and tetR, the repressor gene and this region has been sequenced (Klock *et al.*, *J. Bacteriol.* 161:326-332, 1985). These genes are located on adjacent BglIII-SmaI and SmaI-SmaI fragments. The BglIII site is unique in RP4 but there are five SmaI sites (Lanka, Lurz and Furste, *Plasmid* 10: 303-307, 1983).

25

(i) Cloning the tetA + tetR genes

The plasmid RP4 is well documented (Datta *et al.*, *J. Bacteriol.* 108: 1244, 1971) and is freely available. Furthermore, the plasmid RP4 has been deposited with the National Collection of Type Cultures, 61 Colindale Avenue, London, NW9 5HT under accession numbers 50078 and 50437. RP4 obtained from N Datta (National Collection of Type Cultures) was used herein. *E. coli* strains containing this plasmid were grown in selective broth cultures and plasmid DNA was isolated by a scale-up of the Holmes and Quigley method (Holmes and Quigley, *Anal. Biochem.* 114: 193-197, 1981). It was deproteinized by treatment with 2.5M ammonium acetate and reprecipitated with isopropanol. This plasmid DNA was treated, according to the supplier's recommended conditions, with restriction enzyme BglIII and cut to completion. It was then partially cut by XmaI by using diluted enzyme and short incubation times. XmaI is an isoschizomer of SmaI but which produces 4-nucleotide cohesive ends at its cut sites.

30

35

The vector plasmid pUC8 (Yanisch-Perron, Vieira and Messing, *Gene* 33: 103-119, 1985) was similarly prepared and cut with BamHI and XmaI to completion. The RP4 fragments were cloned into this vector by ligation with T4 ligase at 12°C for 16 hours. This was used to transform *E. coli* C600 made competent by the calcium chloride method (Maniatis *et al.*, Cold Spring Harbor Laboratory, 1982). Cultures were then plated onto medium which selected for tetracycline resistance.

40

E. coli C600 is freely available from numerous sources including many culture collections such as the *E. coli* Genetic Stock Centre, Yale University, USA under accession number GCSC 3004. The genotype of *E. coli* C600 is K12 thr-1 leuB6 thi-1 lacY1 tonA21 λ^- supE44.

45

Several colonies with this resistance were checked for the expected phenotype (ampicillin and tetracycline resistance but not the kanamycin resistance indicative of RP4 itself). Colonies with the correct resistances were subjected to clone analysis by isolating plasmid DNA (Holmes and Quigley method). These preparations were cut with EcoRI and HindIII and analysed by gel electrophoresis. This established the size of the cloned insert which was found to be the 2.45 kb predicted for the BglIII - XmaI - XmaI fragment from RP4. A clone carrying this fragment containing the tetA and tetR genes was designated pTB344. (Figure 2)

50

(ii) Removal of the tet gene from pAT153

It was necessary to remove the tet gene from the vector plasmid pAT153 before inserting the tetA + tetR cassette from RP4 to prevent gene duplication which can be a source of genetic instability. Also the tet gene may not be effectively suppressed by the non-cognate tetR. The removal was done by isolating plasmid pAT153 DNA and cutting it with EcoRI and AvaI. Between these sites, synthetic oligonucleotides with the following sequence (SEQ IN NO. 40):-

55

5' AATTCGCATGCGGATCCATCGATC3'
 3' GCGTACGCCTAGGTAGCTAGAGCC5'

5 were cloned. These fit the EcoRI and AvaI cohesive ends and contain SphI, BamHI and ClaI sites in addition. After transformation and selection, colonies were tested for the loss of the tetracycline resistance determinant. Plasmid DNA from one clone was sequenced to confirm that the predicted sequence was correct. This plasmid was designated pICI0019. (Figure 3)

10 (iii) Insertion of the tetA + tetR genes

The tetA and tetR genes were isolated from pTB344 on an EcoRI to PstI fragment. The pUC8 vector was destroyed by cutting with SspI because it carries the same selection determinant (ampicillin resistance) as pICI0019. Plasmid pICI0019 DNA was cut with EcoRI and PstI and then ligated with the 2.45kb fragment carrying the tet genes. This was used to transform E.coli C600, the culture being plated out under selection for tetracycline resistant colonies. The insertion of the tet genes was designed to replace most of the bla gene in pCH19 which should thus lose its ampicillin resistance determinant. Loss of ampicillin resistance from the transformants was confirmed. A few clones were then used to isolate plasmid DNA which was subjected to restriction analysis. This confirmed that the constructed plasmid had the intended structure. It was designated pTB351. (Figure 3)

(iv) Insertion of the cer sequence

25 The naturally-occurring plasmid ColEI is very stably maintained in E.coli, whereas its derivatives pBR322 and pAT153 are not. Summers and Sherratt (Cell, 36: 1097-1103, 1984) demonstrated that this was due to the derivatives not containing a short (283 bp) sequence called cer which is present in the parent plasmid. This sequence contains a site-specific plasmid multimer-resolution system which prevents the accumulation of plasmid multimers formed by homologous recombination. Such multimers have a deleterious effect on the process of partition which normally ensures stable inheritance of daughter plasmids during bacterial cell division.

30 The cer sequence (Summers, D et al MGG, 201, p334-338, 1985) was isolated from plasmid pKS492 (provided by D. Sherratt) as a 289 bp fragment by cutting with BamHI and TaqI. The plasmid pTB351 was isolated as DNA from a dam strain of E. coli to prevent its ClaI site being blocked by the dam⁺ methylation system. This DNA was cut with BamHI and ClaI (both these sites having been introduced on the synthetic oligonucleotide for this cloning). The cer fragment was ligated with the cut vector and then used to transform E. coli C600, selection being made for tetracycline resistance. Transformant colonies were subjected to clone analysis by AvaI restriction and gel electrophoresis. The presence of an extra DNA band of about 300 bp indicated the acquisition of the cer fragment. Further restriction analyses were used to confirm that resultant plasmids had the correct structure. One of these was designated pICI0042 (Figure 3 and 4).

40 (v) Tests on pICI0042

The plasmid has been completely sequenced using the DuPont Genesis 2000 machine. (Figure 3 and 4).

The inducibility of the tetracycline resistance was checked. First the minimal inhibitory concentration (MIC) of tetracycline for (pICI0042)C600 was measured. This was done by inducing a culture of this strain with 0.5 µg/ml of tetracycline. After growth, this culture was serially diluted and plated onto broth media containing levels of tetracycline from 0 to 500 µg/ml to give about 100 colonies per plate. The MIC was found to be about 200 µg/ml. A culture of (pICI0042)C600 was then grown to early log phase in Luria broth in the absence of tetracycline. This was used to inoculate parallel cultures in broth, with and without tetracycline induction. These were grown with aeration at 37°C for 90 minutes to allow induced expression. Serial dilutions of these cultures were then plated onto rich medium with and without 100 µg/ml of tetracycline. The resulting colonies demonstrated that the viability of the uninduced culture was 1600-fold lower than the induced culture on the tetracycline medium. This confirms that the tetA + tetR induction system in pICI0042 is working satisfactorily.

55 The maintenance stability of pTB351 and pICI0042 in E. coli C600 were checked. This was in order to compare them with their parent plasmid pAT153 and note the effect of the cer sequence in pICI0042. Cultures were grown without selection and samples checked for the presence of the plasmid after 50, 100 and 150 generations of growth. We found no plasmid loss by either strain throughout this period. Thus pTB351, even without a cer sequence, appears to have gained stability over its parent pAT153. This may be a consequence of the deletion of its tet gene. Naturally-occurring plasmids always have tetracycline resistance under inducible control so the

constitutive tet gene in pAT153 may be counterselective in the absence of tetracycline. This could be due to the fact that the tetracycline resistance mechanism acts as a cytoplasmic membrane export pump. When not required it may harm the cell by damaging the membrane structure, exporting wanted metabolites or wasting metabolic energy. The presence of the cer sequence in pCI0042 should contribute to plasmid maintenance stability even under the counterselective conditions of using it to express a recombinant gene at high level.

(b) Preparation of Plasmid pCH101

The plasmid pCH101 corresponds to pCI 0020 (see Example 5c) except that the EcoRI-Sall fragment (see Figure 5a) is replaced by a fragment consisting of the SEQ ID No 34 (see Figure 5b also) and the interferon α_2 gene sequence as described by Edge M.D. *et al*, Nucleic Acids Research 1983, Vol11, p6419-6435. In this regard the 3'-terminal ATG codon of SEQ ID No 34 immediately precedes the TGT codon which codes for cysteine (amino acid 1) in the interferon α_2 sequence of the above-mentioned Edge M.D. *et al* Nucleic Acids Research reference. The 5' nucleotide sequence GATCCATG and the complementary 3' nucleotide sequence GTAC are thus omitted from the nucleotide sequence of the aforementioned reference.

(c) Insertion of an Expression Cassette into pCI0042

An expression cassette consisting of the trp promoter, a ribosome binding site and the interferon α_2 gene was isolated from plasmid pCH101 (see b above) on an EcoRI to SphI restriction fragment. This was ligated into the production vector (pCI0042) (see above) similarly cut with EcoRI and SphI. This DNA was used to transform a competent culture of *E. coli* C600 and tetracycline resistant colonies were isolated. A few of these were tested by DNA clone analysis for the acquisition of the SstI restriction site carried on the expression cassette. Clones positive in this respect were further tested by restriction mapping to check that the expected construct was correct. They were also checked for the conferred capacity to produce interferon α_2 protein as analysed on a polyacrylamide-SDS gel stained with Coomassie blue. One such confirmed clone was designated pLB005.

(d) Insertion of T4 transcription terminator into pTB244

The T4 transcription terminator sequence in the form of the Sall to HindIII fragment (67 bases pairs long) (see SEQ ID No. 33 and Figure 1b) was inserted into the multicloning site of an intermediate vector pTB244 (described in European Patent Publication No. 237,269) between its Sall and HindIII sites. Clone analysis was used to confirm the structure of this construct (pTB244-T4 ter). From this vector, an SstI to SphI fragment containing most of the multicloning site and the T4 terminator was then isolated. This was inserted into pLB005 similarly cut with SstI and SphI thereby substituting the interferon α_2 gene but leaving a cassette consisting of the trp promoter, multicloning site and T4 terminator. This construct was confirmed by clone analysis and the plasmid designated pLB013.

(e) Substitution of the multicloning site

The multicloning site in pLB013 is not ideal for this vector in several respects: the Sall, BamHI and SmaI sites are not unique but exist elsewhere on the plasmid. This fragment was therefore excised by cutting with SstI and XbaI (both unique) and synthetic oligonucleotides with the sequence of SEQ ID No. 35:-

5' AGCTCCATATGGTACCAGATCTCTCGAGAGTACTT
GGTATACCATGGTCTAGAGAGCTCTCATGAAGATC 5'

were inserted in its place. Clones were analysed for acquisition of the new restriction sites and then confirmed by sequencing. One such plasmid was designated pLB014. The new cloning sites inserted in this way are: NdeI, KpnI, BglII, XhoI and ScaI with the previous XbaI and Sall following them.

(f) Further modification

It was discovered that the adjacent SstI and NdeI sites in pLB014 could not be cut by both these restriction enzymes either simultaneously or sequentially presumably because of their close proximity. An additional sequence was therefore inserted between them. This was done by cutting pLB014 with SstI and KpnI and then insert-

ing the synthetic oligonucleotide of SEQ ID No. 36:-

5' AGCTCAGCTGCAGCATATGGTAC
GTTCGACGTCGTATAC 5'

5

Clones were analysed for acquisition of an extra PvuII or PstI site and then confirmed by sequencing. One such plasmid was designated pLB015 (= pICl0080) (see Figure 7). This plasmid, unlike pLB014, is efficiently cut by SstI and NdeI. This is to provide a place to insert a variety of ribosome binding site sequences correctly positioned with respect to the upstream trp promoter and with NdeI designed to provide the ATG start codon of the gene to be expressed.

10

EXAMPLE 2

15 Preparation of [Arg¹¹,Ser^{17,27,60,65}]human G-CSF using vector including trp promoter

a) Plasmid pICl1239 (described in Example 7) was digested with EcoRI and Sall in buffer H as described previously. The small EcoRI-Sall fragment containing the trp promoter, ribosome binding site and gene for [Arg¹¹,Ser^{17,27,60,65}]hu G-CSF was isolated from a 0.7% agarose gel by use of GeneClean(TM). A vector fragment was prepared from pICl 0080 (see Example 1f) by digestion with EcoRI and XhoI in buffer H and the large EcoRI-XhoI fragment isolated from a 0.7% agarose gel by use of GeneClean(TM). The small EcoRI-Sall fragment was ligated into the EcoRI-XhoI vector fragment, using a 2:1 molar excess of insert to vector as described previously and the ligation mix used to transform E. coli strain MSD 522. Transformants were selected for growth on L-agar plates containing tetracycline (15µg/ml). Three colonies were selected and grown up in M9 minimal media (75ml) containing supplements and tetracycline (15µg/ml) at 37°C for 20 hours on a reciprocating shaker. Protein accumulation was measured by scanning Coomassie blue stained SDS-PAGE gels of whole cell lysate. All three clones expressed [Arg¹¹,Ser^{17,27,60,65}]hu G-CSF. Plasmid DNA from one of the colonies was designated pICl1327 and the sequence of the promoter and gene confirmed by standard dideoxy sequencing procedures as described previously.

30 b) Fermentation

pICl 1327 was transformed into E. coli strain MSD 522 and the resultant recombinants purified and maintained on glycerol stocks at -80°C.

An aliquot of the culture was removed from stock and streaked onto agar plates of tetracycline to separate single colonies after overnight growth at 37°C. A single desired colony was removed and resuspended in 10 ml tetracycline broth and 100µl immediately inoculated into each of 3 250 ml Erlenmeyer flasks containing 75 ml tetracycline broth. After growth for 16h at 37°C on a reciprocating shaker the contents of the flasks were pooled and used to inoculate a fermenter containing 20L growth medium.

40

45

50

55

Composition of Growth Medium

Made up of distilled water

| | | |
|----|---|-----------------------|
| 5 | | <u>g/l</u> |
| | KH ₂ PO ₄ | 3.0 |
| | Na ₂ HPO ₄ | 6.0 |
| 10 | NaCl | 0.5 |
| | Casein hydrolysate (Oxoid L41) | 2.0 |
| | (NH ₄) ₂ SO ₄ | 10.00 |
| | Yeast Extract (Difco) | 10.00 |
| 15 | Glycerol | 35.00 |
| | L-Leucine | 0.625 |
| | MgSO ₄ · 7H ₂ O | 0.5 |
| 20 | CaCl ₂ · 2H ₂ O | 0.03 |
| | Thiamine | 0.008 |
| | FeSO ₄ /Citric Acid | 0.04/0.02 |
| | Trace element solution (TES) | 0.5ml l ⁻¹ |
| 25 | Tetracycline | 10mg l ⁻¹ |

30 Fermentations were then carried out at a temperature of 37°C, and at a pH, controlled by automatic addition of 6M sodium hydroxide solution, of pH 6.7. The dissolved oxygen tension (dOT) set point was 50% air-saturation and was initially controlled by automatic adjustment of the fermenter stirrer speed. Air flow to the fermenter, initially 20L/min, corresponding to 1 volume per volume per minute (VVM) was increased to 50L/min (2.5 VVM) when the fermenter stirrer speed approached 80-90% of its maximum. Since the oxygen transfer rate (OTR) of the fermenters was unable to meet the oxygen uptake rate (OUR) of the bacteria at a cell density greater than that corresponding to an OD₅₅₀ of 50 under the conditions described, dOT in the fermenter at cell densities greater than this was maintained at 50% air-saturation by restricting bacteria oxygen uptake rate. This was achieved by formulating the medium to become carbon-limited at OD₅₅₀ of 50 and then supplying a feed of the limiting carbon source, together with ammonium sulphate and yeast extract, at a rate which restricted bacterial growth rate.

40 Fermentations were performed for 18h and during that time samples were taken for measurement of optical density (OD₅₅₀), cell dry weight and accumulation of [Arg¹¹,Ser^{17,27,60,65}]human G-CSF within the cells. [Arg¹¹,Ser^{17,27,60,65}]human G-CSF accumulation was measured by scanning Coomassie blue stained SDS-PAGE gels of whole cell lysates of the sampled bacteria as is well known in the art.

When OD₅₅₀ reached 35 (8.5h), casein hydrolysate solution (100g/l Oxoid L41) was pumped into the fermenters at a rate of 0.75g/l/h.

45 When OD₅₅₀ reached approximately 50, the supply of carbon-source in the fermentation batch became exhausted leading to a rapid rise in dOT from 50% air saturation. At this point, a feed containing glycerol (470g/l), yeast extract (118g/l) and ammonium sulphate (118g/l) was pumped into the fermenters at a rate which returned and then maintained the dOT at 50% air saturation with the fermenter stirrer at ca 70-80% of its maximum. Casein hydrolysate feeding was maintained at 0.75g/l/h throughout. After approximately 18 hours, when microscopic examination of the culture showed the presence of large inclusion bodies within a majority of the cells, bacteria were harvested on a Sorval RC3B centrifuge (7000g, 30 min., 4°C) and stored frozen at minus 80°C.

EXAMPLE 3

55 Preparation of [Arg¹¹,Ser^{17,27,60,65}]human G-CSF using vector including T7A3 promoter

a) An EcoRI-Sall fragment, containing a T7A3 promoter, a trp leader ribosome binding site sequence and a gene for [Ser^{17,27}]hu G-CSF was sub-cloned into M13 mp18 as described in part d) of Example 5. The sequ-

ence of the EcoRI-Sall fragment is set out in SEQ ID No 32 and Figure 9, SEQ ID No 32 consists of the EcoRI restriction site (nucleotides 1-6), the A3 promoter sequence of bacteriophage T7 (nucleotide 7-52), the trp leader ribosome binding site sequence (nucleotides 53-78) and translation initiation codon (nucleotides 79-81). Figure 9 sets out the nucleotide sequence of [Ser^{17,27}]human G-CSF terminating in the Sall restriction site. It will be appreciated that the 3' terminal ATG codon of SEQ ID No 32 immediately precedes the ACT codon which codes for threonine (amino acid 1) in Figure 9. The 5' nucleotide sequence AATTCAGT is thus absent from the EcoRI-Sall fragment. The EcoRI-Sall fragment may also be prepared by excision from pICI 1295 (see Example 8). Site-directed mutagenesis was performed on single-stranded DNA as described in the protocol described in Example 7 using oligonucleotide SEQ ID No 28 to convert the codon for Gln at position 11 to Arg. Double-stranded RF DNA was prepared from a plaque containing the Gln¹¹→Arg¹¹ change as described in Example 6, except that at step B3 incubation was for 3 hours instead of 5 hours, and digested with EcoRI (as described previously) and SnaBI (10 units, 1xM buffer, BCL, 30µl, 2 hours, 37°C). The resulting 144 bp EcoRI-SnaBI fragment containing the T7A3 promoter, trp leader ribosome binding site sequence and gene fragment with Arg¹¹ codon was isolated and ligated to an EcoRI-SnaBI cut vector from pICI 1327 (which contains codons for Ser⁶⁰ and Ser⁶⁵ and is described in Example 2). The ligation mix was used to transform E.coli strain MSD522 and transformants selected for growth on L-agar plates containing tetracycline (15µg/mg). Plasmid DNA from a colony containing the expected T7A3 promoter and [Arg¹¹ Ser^{17,27,60,65}] hu G-CSF gene sequence were identified by sequencing DNA from the isolated plasmid and designated pICI 1386.

The fermentation was effected according to two alternative processes (b) and (c) below. Process (b) was effected at 37°C and after 16 hours fermentation as described, microbial biomass was 35 g/l and [Arg¹¹,Ser^{17,27,60,65}]human G-CSF was estimated to be accumulated to 7g/l fermentation broth. Process (c) was effected at 30°C and the fermentation was accordingly slower because of the lower fermentation temperature. With regard to process(c), after 35 hours, the microbial biomass was 55 g/l and the [Arg¹¹,Ser^{17,27,60,65}]human G-CSF yield was estimated to be accumulated to 15 g/l fermentation broth.

b) E.Coli strain CGSC 6300 (genotype F⁻,λ⁻, lac⁺) obtained from the E.coli Genetic Stock Centre was transformed with plasmid pICI 1386. The resultant strain CGSC 6300 (pICI 1386) was purified and maintained in glycerol stocks at -80°C. An aliquot of the culture was removed from stock and streaked onto agar plates of L-tetracycline to separate single colonies after overnight growth (16h) at 37°C. A single colony of CGSC 6300 (pICI 1386) was removed and resuspended in 10ml L-tetracycline broth and 100µl immediately inoculated into each of twenty 250ml Erlenmeyer flasks containing 75ml of L-tetracycline broth. After growth for 16h at 37°C on a reciprocating shaker the contents of the flasks were pooled, and used to inoculate a fermenter containing 20 litres of modified LCM50 growth medium. The composition of the growth medium is in Table 1.

TABLE 1: Composition of growth medium**Modified LCM50 Growth Medium (A)**

made up with distilled water
g/l

| | | |
|----|---|-------------------------|
| 10 | KH_2PO_4 | 3.0 |
| | Na_2HPO_4 | 6.0 |
| | NaCl | 0.5 |
| 15 | Casein Hydrolysate (Oxoid L41) | 2.0 |
| | $(\text{NH}_4)_2\text{SO}_4$ | 10.0 |
| | Yeast extract (Difco) | 20.0 |
| | Glycerol | 35.0 |
| 20 | $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ | 0.5 |
| | $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$ | 0.03 |
| | Thiamine | 0.008 |
| 25 | FeSO_4 /Citric acid | 0.04/0.02 |
| | Trace element solution(TES) | (0.5ml l^{-1}) |
| | Tetracycline | (10 mg l^{-1}) |

30 The fermentation was then carried out at a temperature of 37°C and at a pH, controlled by automatic addition of 6M sodium hydroxide solution, of pH 6.7. The dissolved oxygen tension (dOT) set point was 50% air saturation and was initially controlled by automatic adjustment of the fermenter stirrer speed. Air flow to the fermenter was initially 20 L/min corresponding to 1.0 volume volume per minute (VVM) and was increased to 45 L/min manually when the fermenter stirrer speed reached its maximum (1000 rpm). The fermentation was performed for 16h and during that time samples were taken for measurement of optical density of the culture (OD₅₅₀ biomass concentration, total microbial protein concentration and accumulation of [Arg¹¹,Ser^{17,27,60,65}]human G-CSF within the bacterial cells. Accumulation was measured by scanning Coomassie blue stained SDS-PAGE gels of whole cell lysates of the sampled bacteria as is well known in the art. Total microbial protein was estimated by the method of Lowry. A solution of yeast extract (225 g/L) was pumped into the fermenter 4.5h post inoculation at 1.7 g/L/h. When the supply of carbon source (glycerol) in the growth medium became exhausted dOT increased rapidly from 50% air saturation. At this point a feed containing glycerol (714 g/l) and ammonium sulphate (143 g/L) was pumped. Since the bacterial oxygen sulphate rate (OUR) approached the maximum oxygen transfer rate of the fermenter (OTR) just prior to the carbon source in the batch growth medium becoming exhausted, the feed was pumped into the fermenter at a rate which restricted the bacterial OUR to approximately 80-90% of the fermenters maximum OTR. The feed rate was adjusted manually to return and then maintain dOT at 50% air saturation under the conditions described.

45 c) The fermentation process described in (b) was repeated but at a temperature of 30°C for 35 hours. Except for the fermentation temperature of 30°C the medium and fermentation conditions were identical to those described in (b).

EXAMPLE 4

Preparation of plasmid pAG88

a) Preparation of a synthetic gene for human G-CSF

A DNA sequence (Figure 10) encoding the amino-acid sequence of the polypeptide of Figure 10 (human G-CSF) was designed according to the following considerations:

- 1) Single - stranded cohesive termini to allow ligation at suitable sites in a plasmid.
- 2) A series of restriction endonuclease sequences throughout the gene to facilitate subsequent genetic manipulation.
- 3) Translation termination codon.
- 4) Codons at the 5'-end of the coding region were normally chosen to be A/T rich. Other codons were normally chosen as those preferred for expression in *E.coli*.

The gene was assembled from the 18 oligonucleotides designated SEQ ID No.1 - SEQ ID No.18 and shown hereinafter.

10 Preparation of Oligonucleotides

The oligonucleotide sequences shown hereinafter were prepared on an Applied Biosystems 380A DNA synthesiser from 5'-dimethoxytrityl base-protected nucleoside-2-cyanoethyl-N,N-diisopropylphosphoramidites and protected nucleosides linked to controlled-pore glass supports on a 0.2 micro mol scale, according to protocols supplied by Applied Biosystems Inc.

Alternatively, the oligonucleotide sequences may be prepared by manual methods as described by Atkinson and Smith in 'Oligonucleotide Synthesis, a Practical Approach' (M. T. Gait, Editor, IRL Press, Oxford, Washington DC, pages 35-81).

In detail, the preparation of the oligonucleotide sequences by use of the Applied Biosystems 380A DNA synthesiser was effected as follows:-

Each oligonucleotide, after cleavage from the solid support and removal of all protecting groups, was dissolved in water (1ml). A solution of 3M sodium acetate (pH5.6; 40µl) and ethanol (1ml) was added to the oligonucleotide solutions (400µl) and the mixtures stored at -70°C for 20 hours. The resulting precipitates were collected by centrifugation (13,000rpm for 10 minutes) and the pellets washed with ethanol:water (7:3) (200µl) then dried briefly in vacuo and dissolved in water (15µl) and 10µl of a formamide/dye mix. (10mM NaOH, 0.5mM EDTA, 0.01% Bromophenol Blue, 0.01% xylene cyanol, 80% formamide).

The oligonucleotides were purified on a 10% polyacrylamide gel in 50mM Tris-borate (pH8.3) containing 8.3M urea. Oligonucleotides of correct length were identified by UV shadowing (Narang et al, 1979 in Methods in Enzymology Vol 68, 90-98) - normally the most prominent band - excised from the gel and electroeluted in 5mM tris-borate (pH 8.3) at 300mV for 3-4 hours. The aqueous solutions were concentrated to about 200µl by treatment with n-butanol (mix, spin and removal of the upper organic layer). The purified oligonucleotides were precipitated at -70°C for 20 hours from a 0.3M sodium acetate solution by addition of ethanol (2.5 volumes).

35 Assembly of gene

Oligonucleotides SEQ ID No2 - SEQ ID No 17 (400pM of each) [as defined hereinafter] were phosphorylated with T4 polynucleotide kinase (3.6 units) for 2 hours at 37°C in 25µl of a solution containing ATP (800pM containing 25pM gamma- ³²P ATP), 100µM spermidine, 20mM MgCl₂, 50mM Tris-HCl (pH9.0) and 0.1mM EDTA. The solutions were heated at 100°C for 5 minutes to terminate the reactions, then mixed in pairs as shown in Table 1 to give duplexes A to I (Oligonucleotides SEQ ID No 1 and SEQ ID No 18 (400mM in 25µl) were used unphosphorylated). 0.3M Sodium acetate (pH5.6, 200µl) and ethanol (850µl) were added and the duplexes precipitated at -20°C for 20 hours. The resulting precipitates were collected by centrifugation and washed with ethanol:water (7:3) then dissolved in water (50µl). The pairs of oligonucleotides were annealed together by first heating the solutions to 100°C for 2 minutes in a boiling water bath. The bath was then allowed to cool slowly to 40°C (about 4 hours). Solutions containing 3 pairs of duplexes were combined as shown (see Table 1), to give groups I to III lyophilised and dissolved in 30µl of a solution containing T4 DNA ligase (1 unit; BRL), 50mM Tris (pH7.6), 10mM magnesium chloride, 5% (w/v) PEG 8000, 1mM ATP, 1mM DTT. (BRL, Focus Vol 8 no 1 Winter 1986) and the DNA ligated at 30°C for 5 minutes followed by 20 hours at 16°C. 3M Sodium acetate (20µl) and water (150µl) was added and the product precipitated by addition of ethanol (750µl) and cooling to -20°C for 20 hours. The precipitate was collected by centrifugation and washed with ethanol (1ml) then dissolved in water (15µl) and formamide/dye mix (10µl) and purified on a 10% polyacrylamide gel in 50mM Tris-borate (pH8.3), 1mM EDTA and 8.3M urea. Bands for strands of appropriate lengths (173-186 bases) were identified by autoradiography and isolated together by electroelution from a single gel slice as described above for individual oligonucleotide sequences. The DNA strands were annealed by first heating an aqueous solution (50µl) at 100°C for 2 minutes, then allowing it to cool to 40°C over 4 hours.

Groups I, II and III were ligated together essentially as described for the group preparation to give as the product, the gene sequence shown in Figure 10. After precipitation, the gene was phosphorylated with T4 polynucleotide kinase as described previously for individual oligonucleotides, then dissolved in water (20µl).

TABLE 1

| 5 | DUPLEX | OLIGONUCLEOTIDE | NUMBER OF BASES IN | |
|----|--------|-----------------------------|--------------------|---------------|
| | | | TOP STRAND | BOTTOM STRAND |
| 10 | A | SEQ ID No 1 + SEQ ID No 2 | 62 | 64 |
| | B | SEQ ID No 3 + SEQ ID No 4 | 60 | 60 |
| | C | SEQ ID No 5 + SEQ ID No 6 | 48 | 51 |
| | D | SEQ ID No 7 + SEQ ID No 8 | 63 | 60 |
| 15 | E | SEQ ID No 9 + SEQ ID No 10 | 63 | 63 |
| | F | SEQ ID No 11 + SEQ ID No 12 | 60 | 63 |
| | G | SEQ ID No 13 + SEQ ID No 14 | 63 | 60 |
| | H | SEQ ID No 15 + SEQ ID No 16 | 60 | 60 |
| 20 | I | SEQ ID No 17 + SEQ ID No 18 | 55 | 53 |
| | I | A + B + C | 170 | 175 |
| | II | D + E + F | 186 | 186 |
| | III | G + H + I | 178 | 173 |

b) Cloning of the synthetic gene for human G-CSF

30 The synthetic gene described above, was cloned into the plasmid vector, pSTP1 (Windass et al, Nucleic Acids Research, 1983, Vol 10, p6639).

For vector preparation, 10µg of STP1 was dissolved in water (37.5µl) and 10 x B restriction buffer (4.5µl) (BCL). the restriction endonuclease Sall (3µl) (BCL, 8 units/µl) was added and the mixture incubated at 37°C for 1 hour until linearised plasmid was predominant over supercoiled and nicked circular forms. The DNA was precipitated with ethanol at 4°C for 30 minutes, washed with ethanol:water (7:3) then dissolved in water (39.5µl), 10X H buffer (4.5µl) (BCL). The restriction endonuclease EcoRI (1µl) (BCL, 90 units/µl) was added and the mixture incubated at 37°C for 1 hour until the large EcoRI-Sall fragment was predominant. The DNA was precipitated at -20°C for 20 hours, washed with ethanol:water (7:3) then dissolved in water (20µl)

40 The large EcoRI - Sall fragment was purified on a 1% preparative agarose gel and electroeluted and precipitated as described previously, then dissolved in water (20µl). For ligation of the synthetic gene, a mixture of vector DNA (2µl of the EcoRI - Sall fragment solution), synthetic gene (5µl of the aqueous solution described previously, 5X ligase buffer (6µl -250mM Tris pH7.6 50mM MgCl₂, 25% W/V PEG8000, 5mM ATP, 5mM DTT exBRL) water (15µl) and T4 DNA ligase (2µl, 1U/µl) was incubated at 16°C for 4 hours. The DNA mix was used directly (either 1µl of neat ligation mix or 2µl of ligation mix diluted 5X with water) to transform E. coli strain HB101. The DNA mixture (1 or 2µl) was added to competent E. coli HB101 cells (20µl, BRL) on ice and the mixture incubated on ice for 45 min then heat shocked at 42°C for 45 seconds. After 2 min on ice, 100µl of SOC buffer (Bactotryptone 2%; Yeast Extract 0.5%; NaCl 10mM; KCl 2.5mM; MgCl₂, MgSO₄ 20mM (10mM each); glucose 20mM) was added and the mixture incubated at 37°C for 1 hour. Aliquots of suspensions were plated onto L plates with 50µl/ml ampicillin. Transformants were screened for the presence of cloned synthetic gene by colony hybridisation analysis using standard methods described in "Molecular Cloning: A Laboratory Manual" by Maniatis et al (Cold Spring Harbor) and in UK Patent Application No 8502605. A total of 100 colonies were streaked onto filters (Schleicher and Schuell), grown at 37°C for 20 hours, lysed and baked. The filter was hybridised at 65°C for 20 hours with a radioactive probe prepared from oligonucleotide sequence SEQ ID No 1 by use of a random-label kit (Pharmacia). Five colonies 1-5 giving a positive hybridisation signal were grown up in L broth at 37°C for 20 hours on a small scale (100ml) and plasmid DNA prepared by centrifugation in a caesium chloride gradient essentially as described in "Molecular Cloning; A Laboratory Manual" by Maniatis et al (Cold Spring Harbor).

The DNA was sequenced by the standard dideoxy chain-termination method as described by Sanger et al

in Proc. Nat. Acad. Sci. USA 74, 5463-5467 (1977) using a Sequenase (Trade Mark) kit (United States Biochemical Corporation). Oligonucleotides SEQ ID No 19 to SEQ ID No 23 (as defined hereinafter and see Table 2) were used as sequencing primers.

TABLE 2

| CODE | PRIMING SITE |
|--------------|-----------------------|
| SEQ ID No 19 | 214-234 top strand |
| SEQ ID No 20 | 333-353 top strand |
| SEQ ID No 21 | 375-395 bottom strand |
| SEQ ID No 22 | 207-227 bottom strand |
| SEQ ID No 23 | 69-93 bottom strand |

The plasmid DNA from clone 5 contained the DNA sequence shown in Figure 10. The plasmid was designated pAG88 and was used to transform competent cells of the following E.coli strain HB101 and CGSC 6300 (hereinafter also referred to as MSD 522) by standard procedures.

EXAMPLE 5

Preparation of M13mp18 template containing [Ser^{17,27}] human G-CSF gene

The procedure for steps a) and b) in Example 4 was repeated with the following modifications:

Oligonucleotides SEQ ID Nos 24, 25, 26 and 27 (as hereinafter defined) replace SEQ ID Nos 1, 2, 3 and 4 (as hereinafter defined) respectively.

c) Cloning of the gene for [Ser^{17,27}] human G-CSF into an expression vector

The gene described above (see Figure 9 and SEQ ID No. 31) was cloned into plasmid vector pIC10020. This vector is a pAT153 based plasmid in which the 651 bp EcoRI-AccI region is replaced by a 167 bp EcoRI

- ClaI fragment (SEQ ID No.30) consisting of:-

(1) a synthetic E. coli trp promoter and trp leader ribosome binding site

(2) a translation initiation codon

(3) a multiple restriction enzyme recognition sequence derived from M13mp18, containing sites for KpnI, BamHI, XbaI, SalI, PstI, SphI and HindIII

(4) a synthetic transcription termination sequence

The DNA sequence of this region is shown in Figure 5a.

The pIC10020 expression vector was digested to completion with KpnI (BCL) in 10mM Tris HCl (pH7.5), 10mM magnesium chloride. The DNA was precipitated with ethanol at -20°C from a solution containing 0.3M sodium acetate and then the 3'- sticky ends were removed by treatment with T4 DNA polymerase for 10 minutes at 37°C as follows:-

DNA (1µg) in water (16µl)

10X T4 polymerase buffer (2µl)

0.33M Tris acetate pH7.9

0.1M Magnesium acetate

0.66M Potassium acetate

5mM dithiothreitol

1mg/ml bovine serum albumin (BSA PENTAX fraction V)

2mM dNTP mixture (1µl)

T4 DNA polymerase (1µl; 2.5 units/µl BCL)

Water (80µl) was added and the mixture extracted with phenol/chloroform (100µl) and then with chloroform (100µl). The DNA was precipitated with ethanol (250µl) at -20°C after addition of 3M sodium acetate (10µl) then digested to completion with SalI (BCL) in 150mM NaCl, 10mM MgCl₂ and 10mM Tris HCl (pH7.5). The Kpn-blunt ended to SalI vector was purified from a 0.7% agarose gel and isolated by use of GeneClean (trademark) fol-

lowing the manufacturer's (Bio101, USA) recommended procedure.

The synthetic gene was isolated from the pSTP1 vectors as follows. The vectors were digested with *ScaI* and *Sall* (both from BCL) in 100mM NaCl, 10mM MgCl₂ and 10mM Tris HCl (pH7.5). The 530 bp fragment was purified from a 0.7% agarose gel and isolated by use of Geneclean (trademark) following the manufacturer's

For ligation, a mixture of the *ScaI* - *Sall* gene fragment (50ng) and the pIC10020 vector fragment (100ng) in 20µl of a solution containing 50mM Tris HCl (pH7.6), 10mM MgCl₂, 1mM ATP, 1mM DTT, 5% w/v PEG 8000 and T4 DNA ligase (2 units; BRL) were incubated at 16°C for 20 hours. The resulting mixture was used to transform competent *E. coli* HB101 cells (as supplied by BRL) as described herein. Transformants were selected for by growth on L-agar plates containing 50µg/ml ampicillin and screened for the presence of the gene by colony hybridisation with a ³²P labelled probe (SEQ ID No 24) as described herein. Plasmid DNA was prepared from 6 positively hybridising colonies, purified by centrifugation in a caesium chloride gradient and the sequence confirmed by dideoxy sequencing as described herein.

The plasmid containing this gene was designated pIC1 1080.

d) Subcloning of an expression cassette containing a gene for [Ser^{17,27}]G-CSF into M13mp18.

The following subcloning was effected to provide a starting point for preparation of the G-CSF derivatives detailed in Examples 3-8.

Plasmid DNA from pIC1080 (purified by caesium chloride density centrifugation) was digested to completion with *EcoRI* and *Sall* (BCL) according to the manufacturer's instructions. The small *EcoRI*-*Sall* fragment containing the *trp* promoter and [Ser^{17,27}]G-CSF gene was isolated from a 0.7% agarose gel by use of Geneclean (trademark). This fragment was cloned into an *EcoRI*-*Sall* cut M13mp18 vector (DNA supplied by Amersham International; enzymes from BCL). The fragments were ligated together in 5x BRL ligation Buffer using BRL T4 DNA ligase (described previously). The ligation mix was used to transfect competent *E. coli* TG1 cells (made competent according to the calcium chloride method of Mandel and Higa described in Molecular Cloning - A Laboratory Manual - Maniatis et al Cold Spring Harbor). The transfected cells were suspended in TY top agar containing 2% X-Gal in DMF and 200µl log phase *E. coli* TG1 cells and were plated on 2x TY agar plates (TY top agar - 8g Bactotryptone, 5g Yeast Extract, 5g NaCl, 3.75g Bacto-agar in 500µl sterile H₂O; TY plates - 8g Bactotryptone, 5g Yeast-extract, 5g NaCl, 7.5g Bactoagar in 500 ml sterile H₂O.)

Four white plaques were picked into 4 x 2 ml 1% *E. coli* TG1 cells in TY broth (8g Bactotryptone, 5g Yeast extract, 5g NaCl in 500ml sterile H₂O) aliquots and grown for 6 hours at 37°C. The 2ml cultures were split into 0.5ml and 1.5ml aliquots. The bacteria were centrifuged out of solution in an Eppendorf, (trademark) microfuge and the supernatants were transferred to sterile eppendorf (trademark) tubes. The 0.5ml aliquots were stored at -20°C as phage stocks. The 1.5ml aliquots were used to prepare single stranded DNA following the method in the Amersham International M13 sequencing handbook (see below). These DNA samples were then sequenced using oligonucleotides SEQ 1D No 22, SEQ 1D No 23 and M13 Universal sequencing primer. The reactions were carried out using the Sequenase kit (trademark) according to the manufacturers instructions. All 4 clones had the correct DNA sequence for [Ser^{17,27}]G-CSF.

Large-scale single stranded DNA preparation

For single stranded DNA preparations of between 200-500µg of DNA/ml, the method in the Amersham International "Oligonucleotide Directed Mutagenesis" was used. A detailed procedure is carried out as follows:-

LARGE - SCALE SINGLE STRANDED DNA PREP:

A. Preparation of 1ml phage stock

1. Pick a single TG1 *E.coli* colony from a glucose/minimal medium plate. Grow overnight in 10ml 2 x TY medium, shaken at 37°C. Add 10µl to 20ml of fresh medium, and shake at 37°C for 3 hours.
2. Inoculate 1ml 2 x TY medium in a 10ml sterile culture tube with 100µl of 3 hour culture from step 1.
3. Inoculate the 1ml culture with a recombinant plaque.
4. Incubate for 4 hours with shaking at 37°C. Transfer to a microcentrifuge tube.
5. Centrifuge for 5 minutes at ambient temperature. Pour supernatant into a fresh tube. Store overnight at 4°C. Set up an overnight culture of TG1 *E.coli* for the next stage.

B. Growth of 100ml phage culture.

1. Inoculate 100ml 2 x TY medium with 1ml of overnight TG1 culture and shake at 37°C to an O.D₅₀₀ of 0.3 .
- 5 2. Add the 1ml phage supernatant from A5 (above) to the 100ml culture.
3. Incubate for 5 hours with shaking at 37°C. Transfer to centrifuge tubes.
4. Centrifuge at 5000 x g for 30 minutes at 4°C.
5. Transfer supernatant to a clean centrifuge tube. Take care not to carry over any cells (retain bacterial pellet for RF DNA preparation)
- 10 6. Add 0.2 volumes of 20% w/v PEG 6000 in 2.5M NaCl to the supernatant. Mix well and then leave to stand for 1 hour at 4°C.
7. Centrifuge at 5000 x g for 20 minutes at 4°C. Discard supernatant.
8. Centrifuge at 5000 x g for 5 minutes, and remove all remaining PEG/NaCl with a drawn out Pasteur pipette.
- 15 9. Resuspend the viral pellet in 500µl water (double distilled) and transfer to a microcentrifuge tube (1.5ml).
10. Centrifuge for 5 minutes in a microcentrifuge to remove any remaining cells. Transfer the supernatant to a fresh microcentrifuge tube.
11. Add 200µl 20% PEG 12.5M NaCl to the supernatant mix well then leave to stand at ambient temperature for 15 minutes.
- 20 12. Centrifuge for 5 minutes, discard supernatant.
13. Centrifuge for 2 minutes. Carefully remove all traces of PEG/NaCl with a drawn out Pasteur pipette.
14. Resuspend the viral pellet in 500µl double distilled water.
15. Add 200µl phenol saturated with 10mM Tris HCl pH8.0, 1mM EDTA. Vortex briefly.
- 25 16. Stand tube for 15 minutes at room temperature.
17. Centrifuge for 3 minutes.
18. Transfer supernatant to fresh tube.
19. Repeat steps 15-18.
20. Add 500µl chloroform and extract aqueous phase twice.
21. Add 50µl 3M sodium acetate and 1ml absolute ethanol. Mix.
- 30 22. Place in a dry ice and ethanol bath for 20 minutes.
23. Centrifuge for 15 minutes.
24. Wash each pellet with 1ml -20°C ethanol. Pour off.
25. Vacuum dry pellet and raise in 50µl double distilled water. This procedure yields 100-200µg single stranded DNA.

EXAMPLE 6

Preparation of pICI 1107

The procedure described in Example 5 was repeated except as follows:-

40 The duplex I was phosphorylated with T4 polynucleotide kinase and digested with MstII (10 units) in 1 X H buffer (BCL; 30µl) for 2 hours at 37°C.

Following precipitation with ethanol, the 143 bp EcoRI-MstII fragment was purified on a 10% polyacrylamide gel containing 7M urea, isolated by electroelution from a gel slice and the DNA strands annealed as described in Example 4.

45 The synthetic EcoRI-MstII fragment described above was cloned into the plasmid vector pAG88 described in Example 4. For vector preparation, pAG88 (10µg) was digested with MstII (20 units; BCL) in 1 X H buffer (BCL; 100 µl) for 2 hours at 37°C. The DNA was precipitated with ethanol from 0.3 M sodium acetate at -20°C then digested with EcoRI (20 units; BCL) in 1 X H buffer (BCL; 100 µl) for 2 hours at 37°C. Following precipitation with ethanol, the large EcoRI-MstII fragment was purified on a 1% agarose gel and purified using GeneClean (trademark) as described by the manufacturer (Bio 101, USA). Colonies containing the synthetic fragment were confirmed by screening with a radioactive probe prepared from oligonucleotide (SEQ 1D No 1) and the correct sequence confirmed by DNA sequencing as described in Example 5 (above). The plasmid containing the gene for [Ser^{17,27}]G-CSF was designated pICI1107.

EXAMPLE 7

Preparation of plasmid pICI 1239

The site-directed mutagenesis procedure described below was employed using the mutagenic template

M13mp18 containing the gene for [Ser^{17,27}]G-CSF described in Example 5 or 6 (above). The mutagenic oligonucleotides used are designated SEQ 1D No 28 and SEQ 1D No 29 (as hereinafter defined).

The triplet ACG in SEQ 1D No 28 serves to convert Gln at position 11 to Arg and the first and last AGA triplets in SEQ ID No 29 serve to convert Pro at positions 65 and 60 to Ser. The mutagenesis was carried out as described below using SEQ ID No 29 in a single priming mutagenesis. This yielded a single plaque which incorporated the Pro 60 Ser and Pro 65 Ser changes. Single stranded DNA was prepared from this plaque as described in the mutagenesis procedure described below. This DNA was used as a mutagenic template in a single priming mutagenesis using SEQ ID No 28 as mutagenic primer. This yielded >100 plaques, 3 of which were screened by DNA sequencing as previously described. All 3 had the full set of changes incorporated. Double - stranded RF DNA was prepared from one of the plaques by following the procedure for large scale preparation of single stranded DNA (step d in Example 5) to step B5. The RF DNA was extracted from the bacterial pellet by the alkali lysis procedure of Birnboim and Doly (Nucleic Acids Research (1979) 7, 1513-1523) and purified by caesium chloride density gradient centrifugation as described in "Molecular Cloning - a Laboratory Manual" by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Publication). The purified RF DNA was digested with EcoRI and Sall in buffer H as described previously and the 619bp fragment, containing the trp promoter, ribosome binding site, translation initiation codon and gene for [Ser^{17,27}]G-CSF isolated from a 0.7% agarose gel by use of GeneClean (TM). The fragment was ligated into an EcoRI-Sall digested pCI0020 vector, using a 2:1 molar excess of insert to vector, with T4 DNA ligase (BRL) and ligase buffer, essentially as described previously. The ligation mix was used to transform E.Coli strain HB101. Transformants were selected for by growth on L-agar plates containing 50µg/ml ampicillin. Colonies were screened for the presence of the inserted DNA by restriction analysis of plasmid DNA prepared by the method of Birnboim and Doly as described in "Molecular Cloning - a Laboratory Manual" Sambrook, Fritsch and Maniatis (Cold Spring Harbor Publication). Plasmid DNA from a colony containing the expected 619bp EcoRI - Sall insert was used to transform E.coli strain MSD522 and designated pCI1239.

Site-directed mutagenesis protocol

The phosphorothioate method of Eckstein and co-workers was used:

Taylor, J W et al Nucleic Acids Research (1985) Vol pp 8749-8764

Taylor, J W et al Nucleic Acids Research (1985) Vol pp 8765-8785

Nakamaye, K et al Nucleic Acids Research (1986) Vol pp 9679-9698

Sayers, J R et al Nucleic Acids Research (1988) Vol pp 791-802

The procedure can be carried out using a kit supplied by Amersham International. The method is outlined below and incorporates changes to the original method with regard to the use of more than one mutagenic oligonucleotide and the incubation temperature for oligonucleotides of greater than 30 bases in length.

1. Annealing mutant oligonucleotide to single stranded DNA template:

| | |
|--|-------|
| Single stranded DNA template (1µg/µl) | 5µl |
| Phosphorylated mutagenic oligonucleotide (1.6pmol/1µl) | 2.5µl |
| Buffer 1 | 3.5µl |
| Water | 6µl |

(Where two mutagenic oligonucleotides were used simultaneously, 2.5µl (1.6pmole/1µl) of each phosphorylated oligonucleotide was added to 5µl single stranded DNA template (1µg/µl) in 3.5µl Buffer 1 and 3.5µl water. Where 3 mutagenic oligonucleotides were used 2.5µl (1.6pmol/µl) of each phosphorylated oligonucleotide was added to 5µl single stranded DNA (1µg/µl in 3.5µl Buffer 1 and 1µl water). The above ingredients were placed in a capped tube in a 70°C water bath for 3 minutes if the oligonucleotide was <30bases in length or in a boiling water bath for 3 minutes if the oligonucleotide was > 30 bases in length. The tube was then placed in a 37°C water bath for 30 minutes.

2. Synthesis and ligation of mutant DNA strand:

To the annealing reaction were added

| | | |
|---|----------------------------|-------|
| | MgCl ₂ solution | 5µl |
| | Nucleotide mix 1 | 19µl |
| | (contains dCTP alpha S) | |
| | water | 6µl |
| 5 | Klenow fragment (6 units) | 1.5µl |
| | T4 DNA ligase (5 units) | 2µl |

The above ingredients were placed in a 16°C water-bath and left overnight.

10 3. Removal of single stranded (non-mutant) DNA using disposable centrifugal filter units.

To the reaction from Step 2 the following ingredients were added:-

Water 170µl

5M NaCl 30µl

15 The 250µl sample was added to the top half of the filter unit and centrifuged at 1500 rpm for 10 minutes at room temperature in a SORVALL RT6000B bench top centrifuge using a SORVALL H1000B swing out rotor. Sample passes through two nitrocellulose membranes which bind the single stranded DNA leaving the double stranded DNA to pass through to the collection tube below.

100µl of 500 mM NaCl were added and respun for 10 minutes to wash through any remaining RF DNA.

The following ingredients were added to the filtrate:-

20 3M Sodium Acetate (pH6.0) 28µl

Cold Ethanol (-20°C) 700µl

The mixture was placed in a dry ice and ethanol bath for 20 minutes and centrifuged in an Eppendorf micro-fuge for 15 minutes. The pellet was then resuspended in 10µl buffer 2.

25 4. Nicking of the non-mutant strand using Nci I.

To the reaction mix from step 3, was added 65µl Buffer 3 and 8 units Nci I (1µl). The mixture was placed in a 37°C water bath for 90 minutes.

30 5. Digestion of non-mutant strand using exonuclease III

To the reaction mix from step 4 was added

500 mM NaCl 12µl

Buffer 4 10µl

35 Exonuclease III (50units) 2µl

The mixture was placed in a 37°C water bath and incubated for 30 minutes at 37°C, 50 units of exonuclease III will digest approximately 3,000 bases in 30 minutes). The mixture was then placed in a 70°C water bath for 15 minutes to inactivate the enzymes.

40 6. Repolymerisation and ligation of the gapped DNA.

To the reaction mix from step 5 was added

nucleotide mix 2 13µl

MgCl₂ solution 5µl

45 DNA polymerase I (4 units) 1µl

T4 DNA ligase (2.5 units) 1µl

The mixture was placed in a 16°C bath for 3 hours.

50 7. Transformation of competent host E. coli TG1 cells with the DNA:

300µl of freshly prepared competent E. coli TG1 cells (prepared following the method of Mandel and Higa) were transformed with 20µl of the reaction mix from step 6 (in duplicate). The transformants were plated out in a lawn of log phase TG1 cells in TY Top agar on TY plates and incubated overnight at 37°C.

55 The E. coli strain TG1 is freely available from for example the E. coli Genetic Stock Centre, Yale University, USA and from Amersham International plc, Amersham-Place, Little Chalfont, Amersham, Buckinghamshire HP7 9NA, England as supplied in their "in vitro" mutagenesis system, oligonucleotide directed kit (Product code RPN 1523).

EXAMPLE 8**Preparation of plasmid pICI 1295 (also referred to as pCG300)****5 (a) Production of pCG54 from pICI1079**

pICI1079 is an ampicillin resistant, pAT153-derived plasmid containing the following elements between the EcoRI and StyI restriction sites:-

- (i) a CI857 from phage λ ;
- 10 (ii) a λP_L promoter;
- (iii) a synthetic ribosome binding site;
- (iv) a synthetic interferon α_2 gene sequence;
- (v) a synthetic transcription terminator sequence, derived from phage T4, between the Sall and StyI restriction sites.

15 The DNA sequence of this transcription terminator is shown in Figure 1(b) and SEQ ID No. 37. pICI1079 is illustrated in Figure 6.

pICI1079 has been deposited under the Budapest Treaty, at the National Collections of Industrial and Marine Bacteria Limited (NCIMB), 23 St. Machar Drive, Aberdeen, AB2 1RY, Scotland, UK. (NCIMB No 40370, date of deposit 19 February 1991).

20 pCG54 was constructed in order to make available an expression vector containing the same promoter, ribosome binding site and transcription terminator sequences as above, ie: λP_L , RBS7 and T4, but lacking gene sequence encoding for production of a specific protein. Such a construct would provide the facility of a basic expression vector containing essential elements allowing transcription and translation for production of any protein of interest which could be introduced into this vector by subsequent cloning events.

25 Construction of the vector was initiated by restriction endonuclease cleavage of pICI1079 at its respective EcoRI and Sall sites. This cleavage step released a vector fragment containing the pICI1079 backbone complete with genes for plasmid replication and antibiotic resistance functions, plus the T4 transcription terminator sequence. The fragment was isolated by agarose gel purification steps using GeneClean for final purification of the DNA fragment.

30 To this vector fragment a second smaller DNA fragment of approximately 1.2Kb in size was introduced. This second fragment may be obtained, for example by DNA synthesis or by site directed or PCR mutagenesis of the small EcoRI-Sall restriction fragment obtained from pICI1079 as described above. This second fragment contained exactly equivalent promoter and ribosome binding site sequences as originally present in pICI1079 and additionally had EcoRI and Sall sites available at its 5' and 3' termini respectively, so providing compatible 35 termini for ligation to the pICI1079 fragment. A ligation reaction in the presence of Gibco-BRL enzyme T4 DNA ligase and its respective buffer, resulted in the formation of the construct pCG54.

Clones containing this construct were originally isolated following transformation of an aliquot of the ligation reaction mixture into *E.coli* competent cells of strain HB101.

40 The construct pCG54 recovered was 3.682Kb in size and contained essential features as outlined on the map featured in Figure 11.

(b) Production of pCG61 from pCG54 (also referred to as pICI54)

45 Synthetic oligonucleotide sequences were designed so as to include both the natural sequence for the T7A3 promoter and also a sequence which would provide an effective translation initiation region to enable correct processing of any polypeptide gene sequence cloned adjacent to it. A suitable candidate sequence for this latter region was identified as RBS1, the trp ribosome binding sequence. Therefore two complimentary oligonucleotides identified as SEQ ID No.38 and SEQ ID No.39 were synthesized to generate a double stranded DNA linker incorporating the T7A3 promoter and RBS1 sequences .

50 Oligonucleotides were prepared as 84mers by the standard protocol using an ABI gene synthesizer. They were designed so that in the double stranded form the synthetic fragments would have restriction endonuclease sites EcoRI and KpnI at the 5' and 3' ends respectively. Due to their length the oligomers could not be purified by means of HPLC and purification was undertaken by means of acrylamide gel electrophoresis using a 10% acrylamide: 7M Urea gel.

55 Prior to purification, the oligomers were first checked on a sizing gel to ensure that not only are they of the correct size but that also the samples prepared contain as their greatest proportion the oligomers required and not a high contaminating proportion of smaller secondary oligonucleotides which result as by-products of synthesis.

The acrylamide gels were prepared by standard methods with ammonium persulphate and N,N,N',N'-tetramethylethylenediamine used as catalysts for gel polymerisation.

Sizing of the oligonucleotides required that they could be visualized after electrophoresis. It was therefore necessary to radioactively label the samples using ^{32}P . This made it possible to assess sample quality following electrophoresis by way of autoradiography.

Oligonucleotide samples were supplied in a crude form unphosphorylated. This factor was made use of for radiolabelling purposes in that the samples could be 'hot' labelled at the 5' termini by phosphorylation using the enzyme T4 polynucleotide kinase.

Oligomers were provided from synthesis in an unphosphorylated form and so after purification each oligomer was individually subjected to a phosphorylation reaction in which ATP was used to phosphorylate the 5' end of each molecule in the presence of T4 polynucleotide kinase. (see Molecular Cloning: A Laboratory manual 2nd Edition, Sambrook, Fritsch and Maniatis, p 5.68-5.71). Once phosphorylated the two complementary oligonucleotides were annealed together to form the double strand DNA duplex containing the T7A3 promoter and the RBS1 sequence.

The vector molecule pCG54 was cleaved with restriction enzymes EcoRI and KpnI. On restriction digestion 2.3kb vector fragment and a 1.1kb fragment containing the λ_{PL} promoter and RBS1 sequence are generated. This cloning step is planned to replace the λ_{PL} -RBS1 sequence by EcoRI to KpnI synthetic fragment comprising the T7A3-RBS1 sequence. The 2.3kb vector fragment resulting from digestion of pCG54 was purified by the usual protocol using agarose gel electrophoresis and GeneClean methodology for removal of DNA from agarose fragments.

The 84bp EcoRI-KpnI synthetic fragment was ligated into the vector molecule prepared above and the ligated DNA used to transform *E.coli* HB101 cells. Selection of positive recombinant clones was by ampicillin resistance. Following transformation a number of colonies containing recombinant plasmid were selected for screening purposes.

The synthetic fragment incorporated into the vector during cloning was of a size (84 mer) such as to make restriction analysis of recombinant plasmid DNA samples inappropriate as a simple screening method. Inserts of such a small size are not readily apparent on agarose gel electrophoresis. The fragment itself contains no internal restriction endonuclease cleavage site which could be diagnostic of its presence. Initial screening of recombinant clones was therefore by the method of colony hybridisation (see Grunstein and Hogness Proc. Natl Acad. Sci 72, 3961 (1975)). Nitrocellulose filters containing immobilized plasmid DNA from the recombinant clones were hybridised against a probe prepared by random radiolabelling of the synthetic annealed oligonucleotide SEQ ID No. 38 and SEQ ID No. 39. The DNA was labelled using $\alpha^{32}\text{P}$ -dCTP and incubation with Klenow polymerase at 37°C for 2 hours. Recombinant colonies which generated a positive hybridisation reaction were selected for plasmid DNA preparation. Plasmid DNA was prepared in each case by a relatively large scale method incorporating CsCl gradient density centrifugation to ensure purity see "Molecular Cloning - A laboratory manual" second edition, Sambrook Fritsch and Maniatis (Cold Spring Harbor Laboratory, 1989) p1.42-1.52. Preparation of DNA by such a method ensures high quality material suitable for use in subsequent cloning manipulations and sequence analysis.

All plasmid DNA isolated from recombinant clones was included in a secondary screen by sequence analysis, to ensure that the oligonucleotide sequence at the cloning junctions and of the T7A3-RBS1 fragment itself was absolutely correct. The sequencing protocol used was that of Sequenase and the sequencing primer selected for use was for example pBR322 UP (pBR322 universal primer). Sequencing was effected using the Sanger dideoxy chain termination sequencing technique. Clones having the correct sequence were designated as the new expression construct pCG61, and contained the T7A3 promoter, RBS1 sequence and the T4 terminator sequence (see Figure 8).

EXAMPLE 9 - PREPARATION OF RICIN A

The following illustrates the use of plasmid pICI0042 in the preparation of ricin A. A DNA sequence coding for the ricin A was inserted into plasmid pICI0042 such that it was under the control of the trp promoter. DNA sequences for ricin A are described, for example, in EP 145,111; Lamb, I.F. *et al.*, Eur. J. Biochem., 1985, 148, 265-270; and O'Hare, M. *et al.*, FEBS Letts., 1987, 216, 73-78. The following describes the preparation of several intermediate stages in the derivation of the particular vector used to prepare recombinant ricin A.

9.1 Synthetic oligonucleotides

Synthetic oligonucleotides were used to introduce specific DNA sequence alterations of the ricin gene. All oligonucleotides subsequently described were prepared on an Applied Biosystems 380A DNA synthesiser from

5'-dimethoxytrityl base-protected nucleoside-2-cyanoethyl-N,N-diisopropylphosphoramidites and protected nucleosides linked to controlled-pore glass supports on a 0.2 micro mol scale, according to protocols supplied by Applied Biosystems Inc.

Each oligonucleotide, after cleavage from the solid support and removal of all protecting groups, was dissolved in water (1ml) and a measurement of absorbance at 260nm used to determine concentration.

9.2 Enzymes

A variety of restriction endonucleases and DNA modifying enzymes were used in the manipulations described below. These were purchased from one of a number of suppliers (Amersham International, Bethesda Research Laboratories, Boehringer Mannheim or New England Biolabs) and used in accordance with the manufacturers instructions with respect to reaction conditions.

9.3 Construction of the pICl expression vectors

9.3 a) pICl0020

As mentioned in Example 5(c), plasmid vector pICl0020 is a pAT153 based plasmid in which the 651 bp EcoRI-AccI region is replaced by a 167 bp EcoRI - ClaI fragment consisting of:-

- (1) a synthetic *E. coli* trp promoter and trp leader ribosome binding site
- (2) a translation initiation codon
- (3) a multiple restriction enzyme recognition sequence derived from M13mp18, containing sites for KpnI, BamHI, XbaI, SalI, PstI, SphI and HindIII
- (4) a synthetic transcription termination sequence

The construction of a plasmid vector containing a synthetic trp promoter sequence is published (Windass *et al* Nuc.Acids Res. 10 p6639-6657, 1982). A promoter fragment was isolated from such a vector after digestion with the enzymes EcoRI and HpaI and purification of the appropriate band from an agarose gel by electro-elution (in "Molecular Cloning - A Laboratory Manual", Maniatis, Fritsch and Sambrook, published by CSH laboratory, second edition 1989 and hereinafter referred to as "Maniatis").

A pair of complementary synthetic oligonucleotides were prepared which would ligate to the HpaI end of the promoter fragment providing the natural trp leader ribosome binding site, a translation initiation codon and a 3' KpnI cloning site. These oligonucleotides were mixed in equimolar concentrations and allowed to anneal by heating to 100°C followed by slowly cooling to room temperature.

The promoter fragment and annealed oligonucleotides were then ligated and the appropriate band isolated from a polyacrylamide gel by electroelution. This fragment was then ligated with an M13mp18 vector derivative containing the trp attenuator sequence (generated from synthetic oligonucleotides) cloned into the HindIII site and introducing an additional ClaI restriction site 3' to the attenuator. The ligated DNA was transfected into E. coli strain JM109 (Yanisch-Perron *et al* Gene, 33, p103, 1985) made competent by the CaCl₂ method (Maniatis, chapter 1p82). After plating out and incubation of the plates, plaques were screened by the method of Benton and Davies (Maniatis, chapter 4p41) using a ³²P labelled probe generated by nick translation of the EcoRI-HpaI promoter fragment isolated previously. Single stranded DNA was prepared from positively hybridising plaques by a standard method (Maniatis, chapter 4p29) and sequenced using the M13 universal primer and the Sanger dideoxy chain termination method as provided in kit form by a number of suppliers eg. Sequenase (United States Bioscience).

RF DNA was prepared from one isolate in which the promoter/ribosome binding site/attenuator sequence had been confirmed. This DNA was digested with EcoRI and ClaI and the appropriate fragment isolated from a polyacrylamide gel as above. Plasmid pAT153 was digested with the enzymes EcoRI and AccI and ligated with the isolated promoter fragment. Ligated DNA was used to transform competent E. coli HB101 (Bethesda Research Laboratories) and ampicillin resistant colonies selected.

Plasmid DNA from several clones was prepared and DNA sequence derived from the region between the EcoRI and ClaI sites. One clone confirmed as containing the correct promoter/attenuator region was named pICl0020.

This construction is outlined in Fig.12.

9.3 b) pICl1079

As mentioned in Example 8(a), plasmid vector pICl1079 is an ampicillin resistant, pAT153-derived plasmid containing the following elements between the EcoRI and StyI restriction sites:-

- (i) a CI857 gene from phage λ ;
- (ii) a λP_L promoter;
- (iii) a synthetic ribosome binding site;
- (iv) a synthetic interferon $\alpha 2$ gene sequence;
- (v) a synthetic transcription terminator sequence, derived from phage T4, between the *Sall* and *Styl* restriction sites. The DNA sequence of this transcription terminator is shown in Figure 1b. pICI1079 is illustrated in Figure 6.

pICI1079 has been deposited under the Budapest Treaty. The deposit has been made at the NCIMB, 23 St Machaer Drive, Aberdeen, Scotland. The date of deposit was 19 February 1991 and the number is NCIMB 40370.

This plasmid was used to provide a source of the T4 transcription terminator for the generation of the ricin A expressing clone pICI1185 (see 9.5.d below). The starting point for the generation of this plasmid was pICI1043. pICI1043 is a plasmid based on pICI0020 (see 9.3.a above) in which an expression cassette containing a λP_L promoter and interferon $\alpha 2$ gene (Edge et al Nuc.Acids Res. 11 p6419-6435, 1983) is present between the *EcoRI* and *Sall* sites.

A complementary pair of oligonucleotides was synthesised to generate the transcription terminator from gene 32 of bacteriophage T4 with 5' *Sall* and 3' *SphI* cohesive ends. This fragment was ligated with a plasmid fragment isolated from pICI1043 which had been digested to completion with *Sall* and *SphI*. The intermediate plasmid thus produced (pICI1078) contained both the T4 terminator and *trp* attenuator sequences in tandem.

A second pair of complementary oligonucleotides was then used to replace the *trp* attenuator sequence (and remaining part of the tetracycline resistance gene) by insertion between the *SphI* and *Styl* sites of pICI1078. A unique *BamHI* site was introduced within this synthetic fragment.

These manipulations are outlined in Fig. 13.

9.4 Generation of a ricin A expressing clone

9.4 a) Preparation of pUC8RA plasmid DNA

A clone (pUC8RA) was generated which contains the DNA coding for ricin A. This clone contains A-chain cDNA from base number -74 in the leader sequence through to the *BamHI* site within the B-chain (base number 857) according to the published cDNA sequence (Lamb, I.F., Roberts, L.M., Lord, J.M. Eur.J.Biochem, 1985, 148, p265-270) in plasmid pUC8 (Vieira, J and Messing, J. Gene, 19, p259, 1982). In addition, site-directed mutagenesis has been used to generate a translation termination codon immediately 3' to the final codon of mature ricin A (as reported in O'Hare, M et al FEBS Letts, 1987, 216, p73-78). The entire A-chain coding region is included in a *BamHI* fragment from this clone.

A small quantity of pUC8RA plasmid DNA was obtained from the originators. For future stocks, a dilution of this DNA was used to transform into *E.coli* DH5 α competent cells (Bethesda Research Laboratories) and an ampicillin resistant transformant selected. Plasmid DNA from this clone was prepared by a modified Birnboim-Doly procedure (Maniatis, chapter 1p25). Samples of this DNA were digested with *BamHI* and *BanI* separately and compared to corresponding digests of the original sample of DNA after electrophoresis on an agarose gel. No differences in restriction pattern were observed and, on this basis, the two DNA samples were assumed to be identical.

9.4 b) Sub-cloning into M13

BamHI digests of pUC8RA plasmid DNA and RF (replicative form) DNA from the phage M13 strain K19 (Anglian Biotechnology) were "shotgun" ligated using standard conditions (Maniatis, chapter 1p68). Control ligations were also performed. The ligated DNAs were used to transform *E.coli* strain TG1 (Gibson, 1984/Anglian) made competent by the $CaCl_2$ method (Maniatis, chapter 1p82).

The transformation frequencies indicated efficient ligation and recombinant phage were expected in the progeny. Recombinant phage were predicted to produce clear plaques on IPTG + X-gal (BRL) containing plates due to disruption of the *lacZ* (β -galactosidase) gene. Wild type phage produce blue plaques due to conversion of the X-gal by β -galactosidase.

Several clear plaques were picked for single strand DNA preparation. Direct gel electrophoresis of lysed phage suspensions indicated that one phage clone contained a sizeable insert which was confirmed by sequencing to be the ricin A-chain coding sequence. Only 182 bases of the mature ricin A coding sequence were confirmed but this was taken as sufficient evidence for the presence of the entire ricin A gene. This clone was named M13K19RA.

by phenol extraction of an excised gel slice according to the manufacturer's protocol.

pIC10020 (see 9.3a) was digested with KpnI and then dephosphorylated using calf intestinal alkaline phosphatase (CIP - Boehringer Mannheim). The latter treatment prevents recircularisation of the vector upon ligation which would lead to a high proportion of parentals in the transformation progeny.

Ligations were set up with ratios of plasmid vector to isolated fragment from 8:1 (w/w) to 1:3 for the various strategies. Control ligations to test the effectiveness of phosphatase treatment, ligase activity etc., were included. The ligation conditions were appropriate for the source of T4 DNA ligase used (New England Biolabs or Amersham). Reactions were generally incubated at 15°C overnight.

Fifty percent of each ligation (5µl) reaction was diluted to 100µl with 1 x TNE (50mM Tris, 50mM NaCl, 1mM EDTA) and 200µl of competent E.coli DS410 added. After a standard transformation protocol (Maniatis, chapter 1p74), the cells were plated onto L agar plus streptomycin (25µg/ml) and ampicillin (100µg/ml) and incubated at 37°C overnight. E.coli DS410 has a chromosomal streptomycin resistant gene.

The transformation plates were examined after incubation. In general, 5 to 10 times more colonies were seen in ligations compared to controls without ligase. In some cases, little difference in the number of colonies produced in the presence or absence of ligase occurred indicating incomplete digestion of the vector or poor ligase activity.

Transformants, plus the relevant controls were picked onto nitrocellulose filters placed on L agar plates for hybridisation screening (based on the method of Grunstein and Hogness as described in Maniatis, chapter 1p98). After incubation, the colonies were lysed in situ using 10% SDS and 1M NaOH, neutralised using 1M Tris (pH 7.5) and dried under vacuum at 80°C for 2 hours.

Hybridisation probes were generated by ³²p labelling of the mutational oligonucleotides using T4 polynucleotide kinase. The filters were probed at room temperature and then washed in stages up to 55-65°C to remove non-specifically bound counts before autoradiography. Specific hybridisation indicated putative clones containing ricin A DNA.

Small scale DNA preparations (by the methods of Holmes and Quigley or Birnboim-Doly as specified in Maniatis, chapter 1p25) were made from positively hybridising clones. The DNAs were digested with the relevant restriction enzymes eg. KpnI and EcoRI/BglII, and analysed by electrophoresis on agarose gels. Vector DNAs and mutated RF DNAs were cut with the same enzymes to demonstrate the fragment sizes expected for the correct clones.

Larger scale plasmid DNA preparations (Birnboim-Doly) of each clone were used for more detailed restriction analysis, eg. Clal, HindIII, BamHI, EcoRI/BglII KpnI, and ScaI. On agarose gels, these digests showed the size of fragment inserted, an indication of its orientation and the gain of some unique ricin A-chain enzyme sites.

9.4.e) Expression studies

The clones positively identified by hybridisation and restriction screening were tested for expression of ricin A by SDS-PAGE analysis of total cell lysates. The standard conditions for expression studies were:-

1) Inoculate 10ml of L-broth + antibiotic(s) with a single colony and grow at 37°C overnight with gentle shaking.

2) Take 750µl of the L-broth overnight and pellet the cells in a microfuge (1 min at 6500 rpm).

3) Resuspend pellet in 300µl M9 medium (Maniatis, appendix A.3) + 0.02% casein hydrolysate + 0.2% glucose + 50µg/ml thiamine and inoculate into 10ml of same.

4) Incubate for 7 hours or overnight at 37°C with gentle shaking.

5) After incubation, measure OD₅₄₀, pellet the cells and resuspend to OD₅₄₀ = 10 per ml in Laemmli sample buffer (Maniatis, chapter 18p53). Boil for 15 minutes.

6) Load 20µl of total cell lysate on an SDS polyacrylamide gel, electrophorese, stain with Coomassie blue, destain and visualise.

Of the clones studied by SDS-PAGE, only 1 showed an additional band with equivalent molecular weight of ~29KD (equivalent to that estimated for unglycosylated, mature ricin A). Gel scans indicated the expression level to be in the range of 5-10% of total cell protein. This clone was named pIC1102.

The construction of pIC1102 is outlined in Fig.14. Results of expression studies are shown in Figs.15 and 16.

9.4 f) Western transfers and immunodetection of recombinant ricin A

Authenticity of recombinant ricin A-chain protein, initially observed by Coomassie blue staining of SDS-

polyacrylamide gels, was confirmed by Western blotting. The protein bands were transferred to nitrocellulose filters and detected using a ricin A specific antibody followed by peroxidase labelled antiglobulins.

15% SDS-PAGE gels were run overnight at 8mA then equilibrated for at least 30 minutes in transfer buffer.

Protein bands on the gels were then transferred to nitrocellulose membranes (Hybond-C, Amersham) electrophoretically in a Bio-Rad Trans Blot apparatus at 70V for 3 hours. The filters could be stored, after drying, in sealed plastic bags at -20°C.

Ricin A.1 was a polyclonal antibody raised in rabbits against a synthetic peptide fragment of ricin A. Preliminary studies showed good affinity for ricin A but considerable cross-reactivity with many *E.coli* proteins. To overcome the high background caused by this cross-reactivity the antibody was pre-incubated with an *E.coli* lysate.

Thus, a 10ml L-broth overnight culture of *E.coli* strain DS410 was centrifuged at 4000 rpm for 10 minutes to pellet the cells. The pellet was resuspended in 5ml of bacterial buffer and sonicated at 4-6μ for 6 x 10 second bursts with 30 seconds cooling intervals on ice.

0.5ml of sonicate was then mixed with 0.5ml of ricin A.1 antiserum and incubated at room temperature for 90 minutes. Cell debris was spun down at 13000 rpm for 5 minutes and the supernate stored at -20°C.

The nitrocellulose filters from Western transfers were blocked by incubation overnight at room temperature in 5% BSA-PBS/Tween. (PBS Tween = 5ml Tween 20 per 1 litre of PBS).

Washed 3 x 3 minutes in PBS/Tween.

Incubated 2 hours (or overnight) at room temperature with a 1/4000 dilution of "blocked" Ricin A.1 antibody in 0.5% BSA-PBS/Tween.

Washed 3 x 3 minutes in PBS/Tween.

Incubated 1 hour with a 1/1000 dilution of goat anti rabbit antiserum in 0.5% BSA-PBS/Tween at room temperature.

Washed 3 x 3 minutes in PBS/Tween.

Incubated 1 hour with a 1/5000 dilution of rabbit peroxidase anti-peroxidase antiserum in 0.5% BSA/PBS/Tween at room temperature.

Washed 3 x 3 minutes in PBS/Tween.

Developed by immersion in a solution of 4-chloronaphthol (60mg) in 20ml methanol made to 120ml with PBS and containing 12μl hydrogen peroxide. The membrane was removed from the solution as soon as bands were visible, dried and photographed.

A typical Western blot analysis is shown in Fig.17.

9.4 g) Biological assay for recombinant ricin A protein

The aim here was to establish conditions under which samples generated during the ricin A-chain purification from *E.coli* cells could be tested for biological activity in a cell-free *in vitro* protein synthesis assay.

Rabbit reticulocyte lysates were prepared according to the method of Allen and Schweet (J Biol Chem (1962), 237, 760-767). The assay demonstrates inhibition of protein synthesis in a cell-free system by a lack of incorporation of ¹⁴C-labelled leucine into newly synthesised protein.

9.4 g.i) The assay protocol

Stock solution: 1mM amino acid mix minus leucine.

A solution containing all L-amino acids at 1mM except leucine (adjusted to pH7.4 with NaOH and stored at -70°C).

Soln. A

40mM Magnesium acetate

2M Ammonium acetate

0.2M Tris

(pH 7.4 with HCl, stored 4°C)

Soln. B

ATP (Sigma A5394) 246mg/ml

GTP (Sigma G8752) 24.4mg/ml

Assay mix: 1ml Amino acid mixture

1ml Soln. A

0.1ml Soln. B

103mg Creatine phosphate

1mg Creatine kinase

510µl H₂O

600µl (60µCi) L-¹⁴C-leucine (New England Nuclear, NEC-279E)

Reaction mix: Test sample 25µl

Assay mix 12.5µl

Rabbit reticulocyte lysate 25µl

Blank solution was 2mg/ml BSA in PBS

All assays were done in duplicate

12.5µl of assay mix placed in sterile glass tubes 25µl of BSA in PBS added to each of first four tubes for blanks 25µl of test samples added to rest of tubes 1ml 0.1M KOH added to first two tubes (background blank) Tubes equilibrated to 28°C in a water bath 25µl of rabbit reticulocyte lysate (allowed to thaw from liquid nitrogen temperature) were added to each tube at 20 second intervals. When first tube had incubated for 12 minutes, 1ml 0.1M KOH was added to each tube again at 20 second intervals to allow all tubes to have 12 minutes incubation. Two drops of 20% hydrogen peroxide were added to each tube followed by 1ml of 20% TCA.

Tubes were mixed and allowed to stand for at least 1 hour, or overnight, at 4°C. The precipitates were filtered on to 2.5 cm GFC discs, washed with 3 x 4 ml of 5% TCA, transferred to scintillation vials and 10ml scintillant (Ready-Solv. MP, Beckman) added. After 1 hour the vials were shaken and counted.

9.4 g.ii) Establishment of technique for use with *E.coli* lysates

10ml L-broth overnight cultures were grown at 37°C. 400µl aliquots were pelleted at 13000 rpm for 30 seconds and most of the supernate decanted.

The pellets were subjected to 2 rounds of rapid freezing in dry ice/EtOH followed by thawing at 37°C. 12µl of 25% sucrose in 50mM Tris HC1 pH8.0 were added followed by 4µl of a 10mg/ml solution of lysozyme.

After incubation on ice for 15 minutes, 8µl of 0.25M EDTA were added and incubation continued for 15 minutes. Lysis was brought about osmotically by diluting the samples to 400µl with water. This procedure produced viable cell counts of 80-100 per ml.

When a 25µl aliquot of this lysate was added into the assay reaction mix, the level of incorporation of ¹⁴C-leucine into newly synthesised protein was ~10% of the blank without lysate. This was a similar level of inhibition to that produced by 8ng/ml ricin A. Dilutions of the *E.coli* lysate were then prepared and the assay repeated. The result clearly showed that a minimum 16-fold dilution was necessary to reduce the effect of the lysate to equal that of the blank.

In order to be as confident as possible that lysis of *E.coli* and *E.coli* lysates would not compromise ricin A toxicity, 2 control assays were performed. The first added plant-derived ricin A to a 16X diluted *E.coli* cell pellet so as to give a final concentration of 8ng/ml in the assay mix after cell lysis. Both these controls showed no deleterious affect from the lysates or the lysis procedure on the inhibitory action of ricin A.

These techniques were used to verify the synthesis of biologically active, recombinant ricin A from pIC1102 and the clones described below.

9.4 h) DNA sequence analysis

Plasmid DNA sequencing was used to analyse pIC1102. The protocol chosen was modified from Zagursky et al (Gene Analysis Techniques Vol 2, N° 5) and involves alkaline denaturation of double stranded plasmid DNA prior to primer annealing and sequencing by a standard procedure such as that provided in kit form by several suppliers, eg. Sequenase (United States Bioscience). By using an oligonucleotide to prime at the 3' end of β-lactamase and several A-chain internal primers, sequencing both strands of the promoter and ricin A gene was possible.

The initial sequencing data revealed an unexpected result in that an additional *KpnI* fragment was present between the promoter and ricin A coding sequence, ie:

SEQ.ID.NO. 47

5

KpnI

5' AAAAAGGGTATCGACATGGTACCCGGGGATCCACCTCAGGGTGG

10

KpnI

15

TCTTTCACATTAGAGGATAACAACATGGTACCCAAACAATAC 3'

The additional KpnI fragment has come from M13K19RA and contains restriction enzyme sites plus the part of the ricin leader sequence cloned from pUC8RA. The 5' region of the ricin A chain contains the base changes induced during mutagenesis.

Study of this sequence reveals that the first translation initiation codon (ATG) is out of frame with that the ricin A coding region. Also, there is an in-frame termination codon (TAG) prior to the ricin A initiation codon and a putative Shine-Dalgarno sequence (AGGA) which could re-initiate translation from the second ATG.


Subsequent studies revealed that, surprisingly, this additional DNA fragment conferred a beneficial advantage with respect to the accumulation level of ricin A-chain in E.coli when compared to clones from which it had been excised.

The complete DNA sequence of the ricin A gene contained in pICI1102 is given in Fig.18.


9.5. Generation of subsequent ricin A expressing clones

9.5 a) Mutation of Ricin-A clone pICI1102 to allow subcloning

To subclone the two KpnI fragments from the fortuitously generated pICI 1120 in the correct orientation for ricin-A expression would be difficult. Consequently, we planned to alter the internal KpnI recognition site by a single base substitution (A to T). This would prevent KpnI cleavage at this site and allow the subcloning of a single KpnI fragment into the range of trp/RBS vectors. By substituting the adenine of the KpnI recognition site (GGTACC) with thymine (ie GGTTCC) the first residue of ricin-A is unaltered (GTA/GTT = Val).
ie:



Changed to:



The oligonucleotide synthesised to produce this change has the sequence:

5' A T A C A A C A T G G T T C C C A A A C A A T A C 3'

where the underlined base represents the mutational change:

We planned to clone the mutated ricin-A fragment into a range of trp expression vectors for comparative expression studies. Cloning into pICI0020 provides a comparison with pICI 1102 to determine the effects on expression, if any, of the single base substitution.

9.5 b) Mutagenesis

The template for mutagenesis was MRA16 which is the M13 clone containing the two KpnI fragments present in pICI 1102. After mutagenesis, isolates carrying the desired mutations were identified by random sampling and DNA sequence determination over the region to which the mutagenic oligonucleotide binds specifically.

One mutated template was named MRA22. This was analysed further by DNA sequence determination of the entire ricin-A coding sequence to verify the absence of non-specific mutations.

9.5 c) Sub-cloning

The mutated, single-stranded DNAs were used to transform competent E.coli TG1 cells to produce single plaques. Individual plaques were then picked and replicative form (RF, double-stranded) DNA purified by banding on caesium chloride/ethidium bromide buoyant density gradients. The purified RF DNA was digested to completion with KpnI. Cloning was achieved by "shotgun" ligation of the digested RF DNA with the appropriate KpnI cut and phosphatased expression vector or by specific ligation of the ricin-A fragment after its purification from an agarose gel. Ligated DNA was transformed into E.coli TG1 or HB101.

Ricin-A containing clones were identified by hybridisation screening using a ³²P labelled ricin-A probe produced by random hexanucleotide priming of a KpnI fragment isolated from another ricin A containing clone (pICI 1121). Colonies showing positive hybridisation were screened further by restriction analysis of plasmid DNA using a KpnI single digest and an EcoRI/BglII double digest. KpnI identifies the size of the inserted fragment and EcoRI/BglII determines the orientation of the fragment.

Clones confirmed as having the ricin-A fragment in the correct orientation for expression were subjected to clone selection grows and analysis by SDS-PAGE followed by Coomassie staining and Western blotting of duplicate gels. The level of ricin A accumulation in these clones was equivalent to that detected from pICI1102.

One isolate was selected and named pICI1131.

9.5 d) Use of an alternative transcription terminator element.

In these experiments, the trp promoter and ricin-A fragment from pICI 1131 was excised by digestion with the enzymes EcoRI and Sall. The latter enzyme cleaves between the 3' terminus of the ricin-A coding sequence and the trpA transcription terminator. The resulting fragment was excised from an agarose gel (2% NuSieve GTG Agarose, FMC Bioproducts) and purified by phenol and chloroform extractions followed by ethanol precipitation. The purified fragment was ligated with pICI 1079 cut with EcoRI and Sall. This latter plasmid contains the T₄ terminator between unique Sall and SphI sites.

Ligated DNA was used to transform competent E.coli HB101 (BRL) and hybridisation screening used to detect the presence of ricin-A DNA as in previous experiments. Positively hybridising clones were chosen for plasmid DNA preparation followed by restriction analysis with EcoRI and Sall together to show the presence of an appropriately sized fragment.

One isolate with the correct construction was identified and named pICI1185.

9.5 e) Generation inducible tetracycline selection vector

The clone, pICI1185, was used to produce a further construct by subcloning the expression cassette into a further vector, pICI 0042. Plasmid DNA was prepared from pICI1185 and digested with EcoRI and SphI together to excise an expression cassette containing the trp promoter/RBS1/ricin-A (MRA22) fragment/T₄ terminator. This fragment was isolated by the method outlined in 9.4d and ligated with pICI 0042 cut with EcoRI and SphI.

Ligated DNA was used to transform *E. coli* HB101. HB101 transformations were plated on L agar + tetracycline, and incubated at 37°C overnight and colonies screened by hybridisation with a ³²P labelled ricin-A DNA probe.

In both cases, positively identified colonies were confirmed by restriction analysis of plasmid DNA using *EcoRI*/*SphI* and *EcoRI*/*BglII* digests. Three isolates were identified ie pICI1187.1-3.

Fig.19 outlines the construction of pICI1185 and pICI1187.

9.5 f) Clone selection

The clones isolated were used to transform *E. coli* 71.18 and single colonies picked for clone selection studies. The resulting whole cell lysates were electrophoresed on duplicate SDS-PAGE gels, one of which was stained with Coomassie blue and the other used for Western blot analysis.

The stained gel provided minimal data on ricin-A expression due to the presence of a co-migrating protein from *E. coli* 71.18. Western blotting clearly indicated ricin-A expression in comparison to positive and negative control samples. One isolate was used in the fermentations described below.

RICIN A CHAIN FERMENTATION

Plasmid pICI 1187 was transformed into *E. coli* strain MSD68 and the resultant recombinant (MSD1051) purified and maintained on glycerol stocks at -80°C.

An aliquot of the culture was removed from stock and streaked onto agar plates of L-tetracycline to separate single colonies after overnight growth at 37°C. A single colony of MSD 1051 was removed and resuspended in 10ml L- tetracycline broth and 100µl immediately inoculated into each of 10 250ml Erhlenmeyer flasks containing 75ml L-tetracycline broth. After growth for 16 at 37°C on a reciprocating shaker the contents of the flasks were pooled and used to inoculate a fermenter containing 20L modified LCM50 growth medium.

Composition of Modified LCM50

| | Made up of distilled water |
|---|----------------------------|
| | <u>g/l</u> |
| KH ₂ PO ₄ | 3.0 |
| Na ₂ HPO ₄ | 6.0 |
| NaCl | 0.5 |
| Casein hydrolysate (Oxoid L41) | 2.0 |
| (NH ₄) ₂ SO ₄ | 10.00 |
| Yeast Extract (Difco) | 20.00 |
| Glycerol | 35.00 |
| MgSO ₄ · 7H ₂ O | 0.5 |
| CaCl ₂ · 2H ₂ O | 0.03 |
| Thiamine | 0.008 |
| FeSO ₄ /Citric Acid | 0.94/0.02 |
| Trace element solution (TES) | 0.5ml |

Fermentations were then carried out at a temperature of 37°C and pH, controlled by automatic addition of 6M sodium hydroxide solution, of pH 6.7. The dissolved oxygen tension (dOT) set point was 50% air-saturation and was controlled by automatic adjustment of the fermenter stirrer speed. Air flow to the fermenter, initially 20L/min, corresponding to 1 volume per volume per minute (VVM) was increased to 45L/min when the fermenter stirrer speed approached 80-90% of its maximum.

Throughout the fermentation samples were taken for measurement of optical density (OD₅₅₀), cell dry weight and accumulation of ricin A chain within the cells. Ricin A chain accumulation was measured by scanning

Coomassie blue stained SDS-PAGE gels of whole cell lysates of the sampled bacteria as is well known in the art.

4½ h after inoculation, yeast extract (Difco) solution (225g/L) was pumped into the fermenters at a rate of 1.7g/L/h.

After 12h when OD₅₅₀ reached approximately 50, and before the fermentation became oxygen-limited bacteria were harvested on a Sorval RC3B centrifuge (700g, 30 min, 4°) and accumulated protein recovered from the bacteria.

NOTE:

E. coli DS410 (also referred to as MSD68 herein) is well known (Dougan and Sherratt, Molecular and General Genetics, Vol 151, p151-160, 1977) and has the published genotype F⁻ ara azi ton A lac Y min A min B rps L mal A xyl mtl thi. This strain is freely available to the public, and moreover was deposited by the Applicants on 7 June 1985, under the Budapest Treaty, with the National Collections Of Industrial & Marine Bacteria Ltd, Aberdeen, Scotland under deposition number 12100.

The cells were collected from the fermentation broth using a continuous disc stack intermittent discharge separator. The broth (50l from 2 x 25l fermentation) was initially transferred from the fermenters to a 50l trundle tank and transported to a contained system consisting of a number of holding tanks connected to the separator and homogenizer.

The trundle tank was connected to this system and the broth pumped through the centrifugal separator at a flow rate of 40l/h. The discharge rate was adjusted so that the centrifuge supernatant was clear by visual inspection of an eyeglass in the supernatant discharge line. The supernatant was collected in a kill tank containing .20l of 0.1M sodium hydroxide sanitizing solution prior to disposal. The cells were resuspended in 40l of Buffer A (50mM sodium dihydrogen orthophosphate, 25mM ethylene diamine tetra acetic acid, 5mM benzamidine, 2mM dithiothreitol, pH 6.3 with 5N sodium hydroxide) and prechilled to 8°C in the solids receiver vessel. The suspended cells were then transferred back to the trundle tank via the homogenizer adjusted to a working pressure of 600 bar. The resulting homogenate (60l) was chilled to <20°C and made 0.5% with respect to polythenemine by the addition of 2.5l of a 10% (v/v) solution. The suspension was allowed to flocculate for 10 min before transfer to the Holding Tank via the centrifugal separator. The clear supernatant was then sterilized by purifying through a depth filter and a positively charged 0.2µ membrane filter.

The sterile clarified supernatant was concentrated to a volume of 12l using aspiral cartridge cross flow filtration device and the solution brought to 40% saturation by the addition of 2.9KG of solid ammonium sulphate crystals. The solution was allowed to flocculate by gentle stirring overnight at 15°C and then centrifuged using the continuous flow centrifuge. The discharged slurry was stored at 70°C until required for further processing.

The ammonium sulphate precipitate was thawed in the presence of 14l of Buffer B (50mM sodium dihydrogen orthophosphate, 25mM ethylene diamine tetracetic acid, 2mM dithiothreitol, pH 6.3 with 5N sodium hydroxide). After 30min the suspension was clarified by centrifugation and desalted by diafiltration against 70l of Buffer B and the conductivity checked that it had been reduced to below 3MS/cm. The desalted solution was clarified further by centrifugation and processed immediately.

The desalted solution was slowly added to a batch chromatography tank containing 2kg of DEAE-cellulose which had been equilibrated with 60l of Buffer B. After stirring for 6.5h the unbound r-ricin solution was pumped from the bottom of the tank through an 11.3cm diam x 10cm column of packed and equilibrated DEAE-cellulose at a flow rate of 80ml/min. The bulk of the r-ricin A did not bind and was collected in a stainless steel vessel.

The r-ricin A solution was adjusted to pH 5.5 with 1M orthophosphonic acid and applied to a 10cm diameter x 10cm column of carboxymethyl agarose equilibrated with 10l of Buffer C (25mM sodium dihydrogen orthophosphate, 5mM ethylene diamine tetra acetic acid, 2mM dithiothreitol, pH 5.5 with 5N sodium hydroxide). The r-ricin A bound to this column and after washing with 10l of Buffer C was eluted with Buffer D (25mM sodium dihydrogen orthophosphate, 5mM ethyl diamine tetracetic acid, 2mM dithiothreitol, 100mM sodium chloride, pH 5.5 with 5N sodium hydroxide). The pure r-ricin A eluted as a single peak which was collected and stored at 4°C as a sterile solution until required for further processing. The r-ricin A is stable under these conditions for up to 2 months.

SEQUENCE LISTING

5 The following is a list of the sequences referred to in the application. The sequences are written in the conventional 5' to 3'sense.

10 SEQ ID No 1
 SEQUENCE LENGTH: 62 bases
 SEQUENCE TYPE: Nucleotide
 15 STRANDEDNESS: Single
 TOPOLOGY: Linear
 AATTCAGT ACT CCA CTG GGT CCA GCA AGC TCT CTG CCG CAG TCT TTC 47
 CTG CTG AAG TGT CTC 62

20
 SEQ ID No 2
 SEQUENCE LENGTH: 64 bases
 25 SEQUENCE TYPE: Nucleotide
 STRANDEDNESS: Single
 TOPOLOGY: Linear
 CTG TTC GAG ACA CTT CAG CAG GAA AGA CTG CGG CAG AGA GCT TGC 45
 30 TGG ACC CAG TGG AGT ACTG 64

SEQ ID No 3
 35 SEQUENCE LENGTH: 60 bases
 SEQUENCE TYPE: Nucleotide
 STRANDEDNESS: Single
 TOPOLOGY: Linear
 40 GAA CAG GTA CGT AAA ATT CAA GGC GAT GGT GCG GCT CTG CAG GAA 45
 AAG CTG TGC GCA ACC 60

45

50

55

SEQ ID No 4

SEQUENCE LENGTH: 60 bases

5 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

TTT GTA GGT TGC GCA CAG CTT TTC CTG CAG AGC CGC ACC ATC GCC 45
 10 TTG AAT TTT ACG TAC 60

SEQ ID No 5

15 SEQUENCE LENGTH: 48 bases

SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

20 TAC AAA CTG TGC CAC CCT GAG GAA CTG GTG CTG CTC GGT CAC TCT CTG 48

SEQ ID No 6

25 SEQUENCE LENGTH: 51 bases

SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

30 CGG GAT CCC CAG AGA GTG ACC GAG CAG CAC CAG TTC CTC AGG GTG 45
 GCA CAG 51

35 SEQ ID No 7

SEQUENCE LENGTH: 63 bases

SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

40 TOPOLOGY: Linear

GGG ATC CCG TGG GCT CCA CTG AGC TCT TGC CCG TCC CAA GCT TTA 45
 CAA CTG GCA GGC TGC TTG 63

45

50

55

SEQ ID No 8

SEQUENCE LENGTH: 60 bases

5 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

10 CTG GCT CAA GCA GCC TGC CAG TTG TAA AGC TTG GGA CGG GCA AGA 45

GCT CAG TGG AGC CCA 60

SEQ ID No 9

15 SEQUENCE LENGTH: 63 bases

SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

20 TOPOLOGY: Linear

AGC CAG CTG CAC TCC GGT CTG TTC CTG TAC CAG GGT CTG CTG CAG 45

GCT CTA GAA GGC ATC TCT 63

25 SEQ ID No 10

SEQUENCE LENGTH: 63 bases

SEQUENCE TYPE: Nucleotide

30 STRANDEDNESS: Single

TOPOLOGY: Linear

TTC AGG AGA GAT GCC TTC TAG AGC CTG CAG CAG ACC CTG GTA CAG 45

GAA CAG ACC GGA GTG CAG 63

35

SEQ ID No 11

SEQUENCE LENGTH: 60 bases

40 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

CCT GAA TTG GGG CCC ACC CTG GAC ACA CTG CAG CTG GAC GTT GCC 45

45 GAC TTC GCT ACT ACC 60

50

55

SEQ ID No 12

SEQUENCE LENGTH: 63 bases

5 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

10 TTG CCA TAT GGT AGT AGC GAA GTC GGC AAC GTC CAG CTG CAG TGT
 GTC CAG GGT GGG CCC CAA

45

63

SEQ ID No 13

15 SEQUENCE LENGTH: 63 bases

SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

20 TOPOLOGY: Linear

ATA TGG CAA CAG ATG GAG GAA CTG GGT ATG GCT CCG GCA CTG CAG
 CCG ACT CAG GGT GCG ATG

45

63

25 SEQ ID No 14

SEQUENCE LENGTH: 60 bases

SEQUENCE TYPE: Nucleotide

30 STRANDEDNESS: Single

TOPOLOGY: Linear

TGC TGG CAT CGC ACC CTG AGT CGG CTG CAG TGC CGG AGC CAT ACC
 CAG TTC CTC CAT CTG

45

60

35 SEQ ID No 15

SEQUENCE LENGTH: 60 bases

40 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

45 CCA GCA TTC GCC TCT GCT TTC CAG CGG CGC GCA GGC GGT GTT CTG
 GTT GCC TCC CAT CTT

45

60

50

55

SEQ ID No 16

SEQUENCE LENGTH: 60 bases

5 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

10 GCT CTG AAG ATG GGA GGC AAC CAG AAC ACC GCC TGC GCG CCG CTG 45
GAA AGC AGA GGC GAA 60

SEQ ID No 17

15 SEQUENCE LENGTH: 55 bases

SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

20 CAG AGC TTC CTC GAG GTG TCT TAC CGC GTT CTG CGT CAC CTG GCC 45
CAG CCG TTAG 55

25 SEQ ID No 18

SEQUENCE LENGTH: 53 bases

SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

30 TOPOLOGY: Linear
TCGACTTA CGG CTG GGC CAG GTG ACG CAG AAC GCG GTA AGA CAC CTC 47
GAG GAA 53

35 SEQ ID No 19

SEQUENCE LENGTH: 21 bases

SEQUENCE TYPE: Nucleotide

40 STRANDEDNESS: Single

TOPOLOGY: Linear

TACAACTGGCAGGCTGCTTGA 21

45

50

55

SEQ ID No 20

SEQUENCE LENGTH: 21 bases

5 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

GACGTTGCCGACTTCGCTACT

10

21

SEQ ID No 21

SEQUENCE LENGTH: 21 bases

15 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

TGCCGGAGCCATACCCAGTTC

20

SEQ ID No 22

21

SEQUENCE LENGTH: 21 bases

SEQUENCE TYPE: Nucleotide

25 STRANDEDNESS: Single

TOPOLOGY: Linear

GCCTGCCAGTTGTAAAGCTTG

21

30

SEQ ID No 23

SEQUENCE LENGTH: 26 bases

35 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

GCACCATCGCCTTGAATTTTACGTAG

26

40

SEQ ID No 24

SEQUENCE LENGTH: 62 bases

SEQUENCE TYPE: Nucleotide

45 STRANDEDNESS: Single

TOPOLOGY: Linear

AATTCAGT ACT CCA CTG GGT CCA GCA AGC TCT CTG CCG CAG TCT TTC

47

50

CTG CTG AAG TCT CTC

62

55

SEQ ID No 25

SEQUENCE LENGTH: 64 bases

SEQUENCE TYPE: Nucleotide

5 STRANDEDNESS: Single

TOPOLOGY: Linear

CTG TTC GAG AGA CTT CAG CAG GAA AGA CTG CGG CAG AGA GCT TGC 45

10 TGG ACC CAG TGG AGT ACTG 64

SEQ ID No 26

SEQUENCE LENGTH: 60 bases

15 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

20 GAA CAG GTA CGT AAA ATT CAA GGC AGC GGT GCG GCT CTG CAG GAA 45

AAG CTG TGC GCA ACC 60

SEQ ID No 27

25 SEQUENCE LENGTH: 60 bases

SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

30 TOPOLOGY: Linear

TTT GTA GGT TGC GCA CAG CTT TTC CTG CAG AGC CGC ACC GCT GCC 45

TTG AAT TTT ACG TAC 60

35 SEQ ID No 28

SEQUENCE LENGTH: 29 bases

SEQUENCE TYPE: Nucleotide

40 STRANDEDNESS: Single

TOPOLOGY: Linear

CTT CAG CAG GAA AGA ACG CGG CAG AGA GC 29

45

50

55

SEQ ID No 29

SEQUENCE LENGTH: 33 bases

5 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Single

TOPOLOGY: Linear

10 GC TTG GGA AGA GCA AGA GCT CAG AGA AGC CCA C

32

SEQ ID No 30

SEQUENCE LENGTH: 168 + 166 bases

15 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Double

TOPOLOGY: Linear

20

AATTCTGGCA AATATTCTGA AATGAGCTGT TGACAATTAA TCATCGAACT 50

GACCGT TTATAAGACT TTA CTGACA ACTGTTAATT AGTAGCTTGA 46

25

AGTTAACTAG TACGCAAGTT CACGTAAAAA GGGTATCGAC 90

TCAATTGATC ATGCGTTCAA GTGCATTTTT CCCATAGCTG 86

30

AATGGTACCC GGGGATCCTC TAGAGTCGAC CTGCAGGCAT GCAAGCTTAG 140

TTACCATGGG CCCCTAGGAG ATCTCAGCTG GACGTCCGTA CGTTCGAATC 136

35

CCCGCCTAAT GAGCGGGCTT TTTTTTAT 168

GGGCGGATTA CTCGCCGAA AAAAAATAGC 166

SEQ ID No 31

40 SEQUENCE LENGTH: 534 bases

SEQUENCE TYPE: Nucleotide with corresponding protein

STRANDEDNESS: Single

TOPOLOGY: Linear

45

AATTCAGT ACT CCA CTG GGT CCA GCA AGC TCT CTG CCG CAG TCT TTC CTG 50

Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu

50

1

5

10

55

CTG AAG TCT CTC GAA CAG GTA CGT AAA ATT CAA GGC AGC GGT GCG GCT 98
 Leu Lys Ser Leu Glu Gln Val Arg Lys Ile Gln Gly Ser Gly Ala Ala
 5 15 20 25 30

CTG CAG GAA AAG CTG TGC GCA ACC TAC AAA CTG TGC CAC CCT GAG GAA 146
 10 Leu Gln Glu Lys Leu Cys Ala Thr Tyr Lys Leu Cys His Pro Glu Glu
 35 40 45

CTG GTG CTG CTC GGT CAC TCT CTG GGG ATC CCG TGG GCT CCA CTG AGC 194
 15 Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro Trp Ala Pro Leu Ser
 50 55 60

TCT TGC CCG TCC CAA GCT TTA CAA CTG GCA GGC TGC TTG AGC CAG CTG 242
 20 Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln Leu
 65 70 75

CAC TCC GGT CTG TTC CTG TAC CAG GGT CTG CTG CAG GCT CTA GAA GGC 290
 25 His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly
 80 85 90

ATC TCT CCT GAA TTG GGG CCC ACC CTG GAC ACA CTG CAG CTG GAC GTT 338
 30 Ile Ser Pro Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val
 95 100 105 110

GCC GAC TTC GCT ACT ACC ATA TGG CAA CAG ATG GAG GAA CTG GGT ATG 386
 35 Ala Asp Phe Ala Thr Thr Ile Trp Gln Gln Met Glu Glu Leu Gly Met
 40 115 120 125

GCT CCG GCA CTG CAG CCG ACT CAG GGT GCG ATG CCA GCA TTC GCC TCT 434
 45 Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe Ala Ser
 130 135 140

GCT TTC CAG CGG CGC GCA GGC GGT GTT CTG GTT GCC TCC CAT CTT CAG 482
 50 Ala Phe Gln Arg Arg Ala Gly Gly Val Leu Val Ala Ser His Leu Gln
 145 145 155

55

AGC TTC CTC GAG GTG TCT TAC CGC GTT CTG CGT CAC CTG GCC CAG CCG 530
 Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro
 5 160 165 170 174

TAA G

534

10 SEQ ID No 32
 SEQUENCE LENGTH: 81 bases
 SEQUENCE TYPE: Nucleotide
 15 STRANDEDNESS: Single
 TOPOLOGY: Linear

20 GAATTCAACA AAACGGTTGA CAACATGAAG TAAACACGGT ACGATGTACC 50
 ACAAGTTCAC GTAAAAAGGG TATCGACAATG 81

SEQ ID No 33
 25 SEQUENCE LENGTH: 67 + 67 bases
 SEQUENCE TYPE: Nucleotide
 STRANDEDNESS: Double
 30 TOPOLOGY: Linear

TCGACATTAT ATTACTAATT AATTGGGGAC CCTAGAGGTC CCCTTTTTTA TTTTAAAAAG 60
 GTAATA TAATGATTAA TTAACCCCTG GGATCTCCAG GGGAAAAAAT AAAATTTTTC 56

35 CATGCGA 67
 GTACGCTTCGA 67

40 SEQ ID No 34
 SEQUENCE LENGTH: 118 bases
 SEQUENCE TYPE: Nucleotide
 45 STRANDEDNESS: Single
 TOPOLOGY: Linear

50 AATTCTGGCA AATATTCTGA AATGAGCTGT TGACAATTAA TCATCGAACT 50
 AGTTAACTAG TACGCAGAGC TCAATCTAGA GGGTATTAAT AATGTTCCCA 100
 TTGGAGGATG ATTAAATG 118

55

SEQ ID No 35

SEQUENCE LENGTH: 35 + 35 bases

5 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Double

TOPOLOGY: Linear

10 AGCTCCATAT GGTACCAGAT CTCTCGAGAG TACTT 35
GGTATA CCATGGTCTA GAGAGCTCTC ATGAAGATC 35

15

SEQ ID No 36

SEQUENCE LENGTH: 23 + 15 bases

20 SEQUENCE TYPE: Nucleotide

STRANDEDNESS: Double

TOPOLOGY: Linear

25 AGCTCAGCTG CAGCATATGG TAC 23
GTCGAC GTCGTATAC 15

30

SEQ ID No 37

SEQUENCE LENGTH: 72 + 72 bases

SEQUENCE TYPE: Nucleotide

35 STRANDEDNESS: Double

TOPOLOGY: Linear

40 TCGACATTAT ATTACTAATT AATTGGGGAC CCTAGAGGTC CCCTTTTTTA TTTTAAAAAG 60
GTAATA TAATGATTAA TTAACCCCTG GGATCTCCAG GGGAAAAAAT AAAATTTTTC 56

CATGCGGATC CC 72
45 GTACGCCTAG GGGAAC 72

50

55

SEQ ID No 38
 SEQUENCE LENGTH: 84 bases
 5 SEQUENCE TYPE: Nucleotide
 STRANDEDNESS: Single
 TOPOLOGY: Linear

10
 AAT TCA ACA AAA CGG TTG ACA ACA TGA AGT AAA CAC GGT ACG ATG 45
 TAC CAC AAG TTC ACG TAA AAA GGG TAT CGA CAA TGG TAC 84

15
 SEQ ID No 39
 SEQUENCE LENGTH: 76 bases
 20 SEQUENCE TYPE: Nucleotide
 STRANDEDNESS: Single
 TOPOLOGY: Linear

25
 CAT TGT CGA TAC CCT TTT TAC GTG AAC TTG TGG TAC ATC GTA CCG 45
 TGT TTA CTT CAT GTT GTC AAC CGT TTT GTT G 76

30
 SEQ ID No 40
 SEQUENCE LENGTH: 24 + 24 bases
 SEQUENCE TYPE: Nucleotide
 35 STRANDEDNESS: Double
 TOPOLOGY: Linear

40
 AATTCGCATG CGGATCCATC GATC 24
 GCGTAC GCCTAGGTAG CTAGAGCC 24

SEQ ID No 41
 45 SEQUENCE LENGTH: 174/177 Amino acids
 SEQUENCE TYPE: Amino acid
 TOPOLOGY: Linear

50

55

| | | | | | | | | | | |
|-----|----------|-----|------|-----|-----|-----|-----|-----|-----|-----|
| Thr | Pro | Leu | Gly | Pro | Ala | Ser | Ser | Leu | Pro | Gln |
| 1 | | | | 5 | | | | | 10 | |
| 5 | | | | | | | | | | |
| Ser | Phe | Leu | Leu | Lys | Cys | Leu | Glu | Gln | Val | Arg |
| | | | 15 | | | | | 20 | | |
| 10 | | | | | | | | | | |
| Lys | Ile | Gln | Gly | Asp | Gly | Ala | Ala | Leu | Gln | Glu |
| | | 25 | | | | | 30 | | | |
| 15 | | | | | | | | | | |
| Lys | Leu (Val | Ser | Glu) | m | Cys | Ala | Thr | Tyr | Lys | Leu |
| | 35 | | | | | | | | 40 | |
| 20 | | | | | | | | | | |
| Cys | His | Pro | Glu | Glu | Leu | Val | Leu | Leu | Gly | His |
| | | | 45 | | | | | 50 | | |
| 25 | | | | | | | | | | |
| Ser | Leu | Gly | Ile | Pro | Trp | Ala | Pro | Leu | Ser | Ser |
| | | 55 | | | | | 60 | | | |
| 30 | | | | | | | | | | |
| Cys | Pro | Ser | Gln | Ala | Leu | Gln | Leu | Ala | Gly | Cys |
| | 65 | | | | | 70 | | | | |
| 35 | | | | | | | | | | |
| Leu | Ser | Gln | Leu | His | Ser | Gly | Leu | Phe | Leu | Tyr |
| | 75 | | | | 80 | | | | | 85 |
| 40 | | | | | | | | | | |
| Gln | Gly | Leu | Leu | Gln | Ala | Leu | Glu | Gly | Ile | Ser |
| | | | | 90 | | | | | 95 | |
| 45 | | | | | | | | | | |
| Pro | Glu | Leu | Gly | Pro | Thr | Leu | Asp | Thr | Leu | Gln |
| | | | 100 | | | | | 105 | | |
| 50 | | | | | | | | | | |
| Leu | Asp | Val | Ala | Asp | Phe | Ala | Thr | Thr | Ile | Trp |
| | | 110 | | | | | 115 | | | |
| 55 | | | | | | | | | | |
| Gln | Gln | Met | Glu | Glu | Leu | Gly | Met | Ala | Pro | Ala |
| | 120 | | | | | 125 | | | | |

Leu Gln Pro Thr Gln Gly Ala Met Pro Ala Phe
 130 135 140
 5
 Ala Ser Ala Phe Gln Arg Arg Ala Gly Gly Val
 145 150
 10
 Leu Val Ala Ser His Leu Gln Ser Phe Leu Glu
 155 160
 15
 Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln
 165 170

20
 Pro
 (where m is 0 or 1).

25
 SEQ ID NO 42
 T7A3 PROMOTER SEQUENCE
 SEQUENCE LENGTH: 46 bases
 SEQUENCE TYPE: Nucleotide
 30
 STRANDEDNESS: single
 TOPOLOGY: linear

35
 AACAAAACGG TTGACAACAT GAAGTAAACA CGGTACGATG TACCAC 46

40
 SEQ ID NO 43
 lacO SEQUENCE
 SEQUENCE LENGTH: 22 bases
 SEQUENCE TYPE: Nucleotide
 45
 STRANDEDNESS: single
 TOPOLOGY: linear

50
 AATTGTGAGC GGATAACAAT TT 22

55

SEQ ID NO 44

SEQUENCE LENGTH: 21 bases

SEQUENCE TYPE: Nucleotide

STRANDNESS: single

TOPOLOGY: linear

10 GATAACAACA TATCCCCAA A

21

15 SEQ ID NO 45

SEQUENCE LENGTH: 21 bases

SEQUENCE TYPE: Nucleotide

STRANDNESS: single

20 TOPOLOGY: linear

GATAACAACA TGGTACCCAA A

21

25 SEQ ID NO 46

SEQUENCE LENGTH: 21 bases

30 SEQUENCE TYPE: Nucleotide

STRANDNESS: single

TOPOLOGY: linear

35 AACAAATGG TACCCAAACA A

21

40 SEQ ID NO 47

SEQUENCE LENGTH: 86 bases

SEQUENCE TYPE: Nucleotide

45 STRANDNESS: single

TOPOLOGY: linear

50 AAAAAGGGTA TCGACATGGT ACCCGGGGAT CCACCTCAGG GTGGTCTTTC

ACATTAGAGG ATAACAACAT GGTACCCAAA CAATAC

86

Claims

1. A vector which comprises an inducible selection gene, and a sequence which codes for a heterologous polypeptide.
2. A vector as claimed in claim 1 wherein the selection gene comprises the tetA and tetR genes.
3. A vector as claimed in claims 1 or 2 which includes a DNA sequence which is capable of conferring stability on the vector.
4. A vector as claimed in claim 3 wherein the DNA sequence capable of conferring stability on the vector comprises the cer sequence.
5. A vector as claimed in any one of the preceding claims which includes a transcription terminator as found at the terminus of gene 32 of bacteriophage T4.
6. A vector as claimed in any one of the preceding claims which includes a promoter selected from the trp promoter and the T7A3 promoter.
7. A vector which comprises a replicable plasmidic expression vehicle comprising a promoter, the cer sequence, a transcription terminator as found at the terminus of gene 32 of bacteriophage T4, an origin of replication and a DNA sequence which codes for a heterologous polypeptide.
8. A vector as claimed in any one of the preceding claims wherein the heterologous polypeptide is selected from ricin A and G-CSF or an analogue thereof.
9. A host capable of expressing a heterologous polypeptide, which host comprises a vector as claimed in any one of the preceding claims.
10. A process for preparing a host as defined in claim 9, said process comprising transforming a host by insertion therein of a vector as defined in any one of claims 1 to 8.
11. A process for preparing a polypeptide, said process comprising culturing a host as defined in claim 9 so that polypeptide is expressed.
12. A replicable plasmidic expression vehicle which comprises an inducible selection gene comprising the tetA and tetR genes, and a DNA sequence which codes for a heterologous polypeptide.
13. A host which comprises a replicable plasmidic expression vehicle as defined in claim 12.

TRANSCRIPTION TERMINATION SEQUENCE*Fig.1(a)*SalI

5' TCGACATTATATTACTAATTAATTGGGGACCCTAGAGGTCCCCTTTTTTATTTTAA
3' GTAATATAATGATTAATTAACCCCTGGGATCTCCAGGGGAAAAAATAAAATT

SphI HindIII

AAAGCATGCA 3'
TTTCGTACGTTCGA 5'


*Fig.1(b)*SalI

5' TCGACATTATATTACTAATTAATTGGGGACCCTAGAGGTCCCCTTTTTTATTTTAA
3' GTAATATAATGATTAATTAACCCCTGGGATCTCCAGGGGAAAAAATAAAATT

SphI BamHI StyI

AAAGCATGCGGATCCC 3'
TTTCGTACGCCTAGGGGAAC 5'

Fig. 2.






Fig. 3(cont.)




Fig. 4.




Fig.5(a)

EcoR1

AATTCTGGCA AATATTCTGA AATGAGCTGT TGACAATTAA TCATCGAACT 50
 GACCGT TTATAAGACT TTACTIONGACA ACTGTTAATT AGTAGCTTGA 46

HpaI

AGTTAACTAG TACGCAAGTT CACGTAAAAA GGGTATCGAC 90
 TCAATTGATC ATGCGTTCAA GTGCATTTTT CCCATAGCTG 86

KpnI BamHI XbaI SalI PstI SphI

AATGGTACCC GGGGATCCTC TAGAGTCGAC CTGCAGGCAT GCAAGCTTAG 140
 TTACCATGGG CCCCTAGGAG ATCTCAGCTG GACGTCCGTA CGTTCGAATC 136

ClaI

CCCGCCTAAT GAGCGGGCTT TTTTTTAT 168
 GGGCGGATTA CTCGCCCGAA AAAAAATAGC 166

Fig.5(b)

EcoRI

AATTCTGGCA AATATTCTGA AATGAGCTGT TGACAATTAA TCATCGAACT

HpaI

AGTTAACTAG TACGCAGAGC TCAATCTAGA GGGTATTAAT AATGTTCCCA

TTGGAGGATG ATTAATG

Fig. 6.




Fig. 7.





Fig. 8.



EcoRI ScaI

BNSDOCID: <EP_0502637A2_1 >

Fig. 9(cont.)

NdeI

GAA TTG GGG CCC ACC CTG GAC ACA CTG CAG CTG GAC GTT GCC GAC TTC GCT ACT ACC ATA 359
 CTT AAC CCC GGG TGG GAC CTG TGT GAC GTC GAC CTG CAA CGG CTG AAG CGA TGA TGG TAT
 Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Asp Phe Ala Thr Thr Ile
 100 105 110 115

BssHII

TGG CAA CAG ATG GAG GAA CTG GGT ATG GCT CCG GCA CTG CAG CCG ACT CAG GGT GCG ATG 419
 ACC GTT GTC TAC CTC CTT GAC CCA TAC CGA GGC CGT GAC GTC GGC TGA GTC CCA CGC TAC
 Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met
 120 125 130 135

XhoI

CCA GCA TTC GCC TCT GCT TTC CAG CGG CGC GCA GGC GGT GTT CTG GTT GCC TCC CAT CTT 479
 GGT CGT AAG CGG AGA CGA AAG GTC GAC CGC CGT CCG CCA CAA GAC CAA CGG AGG GTA GAA
 Pro Ala Phe Ala Ser Ala Phe Gln Arg Arg Ala Gly Val Leu Val Ala Ser His Leu
 140 145 150 155

Sali

CAG AGC TTC CTC GAG GTG TCT TAC CGC GGT CTG CGT CAC CTG GCC CAG CCG TAA G 534
 GTC TCG AAG GAG CTC CAC AGA ATG GCG CAA GAC GAC GTG GAC CGG GTC GGC ATT CAGCT
 Gln Ser Phe Leu Glu Val Ser Tyr Arg Val Leu Arg His Leu Ala Gln Pro
 160 165 170 174

Fig.10.

EcoRI ScaI

AATTCAGT ACT CCA CTG GGT CCA GCA AGC TCT CTG CCG CAG TCT TTC CTG CTG AAG TGT 59
 GTCA TGA GGT GAC CCA GGT CGT TCG AGA GAC GGC GTC AGA AAG GAC GAC TTC ACA
 Thr Pro Leu Gly Pro Ala Ser Ser Leu Pro Gln Ser Phe Leu Leu Lys Cys
 1 5 10 15
 SnabI

PspI

CTC GAA CAG GTA CGT AAA ATT CAA GGC GAT GGT GCG GCT CTG CAG GAA AAG CTG TGC GCA 119
 GAG CTT GTC CAT GCA TTT TAA GTT CCG CTA CCA CGC CGA GAC GTC CTT TTC GAC ACG CGT
 Leu Glu Gln Val Arg Lys Ile Gln Gly Asp Gly Ala Ala Leu Gln Glu Lys Leu Cys Ala
 20 25 30 35
 MstII

BamHI

ACC TAC AAA CTG TGC CAC CCT GAG GAA CTG GTG CTG CTC GGT CAC TCT CTG GGG ATC CCG 179
 TGG ATG TTT GAC ACG GTG GGA CTC CTT GAC CAC GAG CCA GTG AGA GAC CCC TAG GGC
 Thr Tyr Lys Leu Cys His Pro Glu Glu Leu Val Leu Leu Gly His Ser Leu Gly Ile Pro
 40 45 50 55
 SacI HindIII


TGG GCT CCA CTG AGC TCT TGC CCG TCC CAA GCT TTA CAA CTG GCA GGC TGC TTG AGC CAG 219
 ACC CGA GGT GAC TCG AGA ACG GGC AGG GTT CGA AAT GTT GAC CGT CCG ACG AAC TCG GTC
 Trp Ala Pro Leu Ser Ser Cys Pro Ser Gln Ala Leu Gln Leu Ala Gly Cys Leu Ser Gln
 60 65 70 75
 XbaI

CTG CAC TCC GGT CTG TTC CTG TAC CAG GGT CTG CAG GCT CTA GAA GGC ATC TCT CCT 299
 GAC GTG AGG CCA GAC AAG GAC ATG GTC CCA GAC GAC GTC CGA GAT CTT CCG TAG AGA GGA
 Leu His Ser Gly Leu Phe Leu Tyr Gln Gly Leu Leu Gln Ala Leu Glu Gly Ile Ser Pro
 80 85 90 95

Fig. 10(cont.)

| | | NdeI | |
|---|---|--------|--|
| 2 | GAA TTG GGG CCC ACC CTG GAC ACA CTG CAG CTG GAC GTT GCC GAC TTC GCT ACT ACC ATA | 359 | |
| | CTT AAC CCC GGG TGG GAC CTG TGT GAC GTC GAC CTG CAA CGG CTG AAG CGA TGA TGG TAT | | |
| | Glu Leu Gly Pro Thr Leu Asp Thr Leu Gln Leu Asp Val Ala Thr Thr Ile | 115 | |
| | | 100 | |
| | TGG CAA CAG ATG GAG GAA CTG GGT ATG GCT CCG GCA CTG CAG CCG ACT CAG GGT GCG ATG | 419 | |
| | ACC GTT GTC TAC CTC CTT GAC CCA TAC CGA GGC CGT GAC GTC GGC TGA GTC CCA CGC TAC | | |
| | Trp Gln Gln Met Glu Glu Leu Gly Met Ala Pro Ala Leu Gln Pro Thr Gln Gly Ala Met | 135 | |
| | | 120 | |
| | | 125 | |
| | | 130 | |
| | | 135 | |
| | | 140 | |
| | | 145 | |
| | | 150 | |
| | | 155 | |
| | | 160 | |
| | | 165 | |
| | | 170 | |
| | | 174 | |
| | | 179 | |
| | | 184 | |
| | | 189 | |
| | | 194 | |
| | | 199 | |
| | | 204 | |
| | | 209 | |
| | | 214 | |
| | | 219 | |
| | | 224 | |
| | | 229 | |
| | | 234 | |
| | | 239 | |
| | | 244 | |
| | | 249 | |
| | | 254 | |
| | | 259 | |
| | | 264 | |
| | | 269 | |
| | | 274 | |
| | | 279 | |
| | | 284 | |
| | | 289 | |
| | | 294 | |
| | | 299 | |
| | | 304 | |
| | | 309 | |
| | | 314 | |
| | | 319 | |
| | | 324 | |
| | | 329 | |
| | | 334 | |
| | | 339 | |
| | | 344 | |
| | | 349 | |
| | | 354 | |
| | | 359 | |
| | | 364 | |
| | | 369 | |
| | | 374 | |
| | | 379 | |
| | | 384 | |
| | | 389 | |
| | | 394 | |
| | | 399 | |
| | | 404 | |
| | | 409 | |
| | | 414 | |
| | | 419 | |
| | | 424 | |
| | | 429 | |
| | | 434 | |
| | | 439 | |
| | | 444 | |
| | | 449 | |
| | | 454 | |
| | | 459 | |
| | | 464 | |
| | | 469 | |
| | | 474 | |
| | | 479 | |
| | | 484 | |
| | | 489 | |
| | | 494 | |
| | | 499 | |
| | | 504 | |
| | | 509 | |
| | | 514 | |
| | | 519 | |
| | | 524 | |
| | | 529 | |
| | | 534 | |
| | | 539 | |
| | | 544 | |
| | | 549 | |
| | | 554 | |
| | | 559 | |
| | | 564 | |
| | | 569 | |
| | | 574 | |
| | | 579 | |
| | | 584 | |
| | | 589 | |
| | | 594 | |
| | | 599 | |
| | | 604 | |
| | | 609 | |
| | | 614 | |
| | | 619 | |
| | | 624 | |
| | | 629 | |
| | | 634 | |
| | | 639 | |
| | | 644 | |
| | | 649 | |
| | | 654 | |
| | | 659 | |
| | | 664 | |
| | | 669 | |
| | | 674 | |
| | | 679 | |
| | | 684 | |
| | | 689 | |
| | | 694 | |
| | | 699 | |
| | | 704 | |
| | | 709 | |
| | | 714 | |
| | | 719 | |
| | | 724 | |
| | | 729 | |
| | | 734 | |
| | | 739 | |
| | | 744 | |
| | | 749 | |
| | | 754 | |
| | | 759 | |
| | | 764 | |
| | | 769 | |
| | | 774 | |
| | | 779 | |
| | | 784 | |
| | | 789 | |
| | | 794 | |
| | | 799 | |
| | | 804 | |
| | | 809 | |
| | | 814 | |
| | | 819 | |
| | | 824 | |
| | | 829 | |
| | | 834 | |
| | | 839 | |
| | | 844 | |
| | | 849 | |
| | | 854 | |
| | | 859 | |
| | | 864 | |
| | | 869 | |
| | | 874 | |
| | | 879 | |
| | | 884 | |
| | | 889 | |
| | | 894 | |
| | | 899 | |
| | | 904 | |
| | | 909 | |
| | | 914 | |
| | | 919 | |
| | | 924 | |
| | | 929 | |
| | | 934 | |
| | | 939 | |
| | | 944 | |
| | | 949 | |
| | | 954 | |
| | | 959 | |
| | | 964 | |
| | | 969 | |
| | | 974 | |
| | | 979 | |
| | | 984 | |
| | | 989 | |
| | | 994 | |
| | | 999 | |
| | | 1004 | |
| | | 1009 | |
| | | 1014 | |
| | | 1019 | |
| | | 1024 | |
| | | 1029 | |
| | | 1034 | |
| | | 1039 | |
| | | 1044 | |
| | | 1049 | |
| | | 1054 | |
| | | 1059 | |
| | | 1064 | |
| | | 1069 | |
| | | 1074 | |
| | | 1079 | |
| | | 1084 | |
| | | 1089 | |
| | | 1094 | |
| | | 1099 | |
| | | 1104 | |
| | | 1109 | |
| | | 1114 | |
| | | 1119 | |
| | | 1124 | |
| | | 1129 | |
| | | 1134 | |
| | | 1139 | |
| | | 1144 | |
| | | 1149 | |
| | | 1154 | |
| | | 1159 | |
| | | 1164 | |
| | | 1169 | |
| | | 1174 | |
| | | 1179 | |
| | | 1184 | |
| | | 1189 | |
| | | 1194 | |
| | | 1199 | |
| | | 1204 | |
| | | 1209 | |
| | | 1214 | |
| | | 1219 | |
| | | 1224 | |
| | | 1229 | |
| | | 1234 | |
| | | 1239 | |
| | | 1244 | |
| | | 1249 | |
| | | 1254 | |
| | | 1259 | |
| | | 1264 | |
| | | 1269 | |
| | | 1274 | |
| | | 1279 | |
| | | 1284 | |
| | | 1289 | |
| | | 1294 | |
| | | 1299 | |
| | | 1304 | |
| | | 1309 | |
| | | 1314 | |
| | | 1319 | |
| | | 1324 | |
| | | 1329 | |
| | | 1334 | |
| | | 1339 | |
| | | 1344 | |
| | | 1349 | |
| | | 1354 | |
| | | 1359 | |
| | | 1364 | |
| | | 1369 | |
| | | 1374 | |
| | | 1379 | |
| | | 1384 | |
| | | 1389 | |
| | | 1394 | |
| | | 1399 | |
| | | 1404 | |
| | | 1409 | |
| | | 1414 | |
| | | 1419 | |
| | | 1424 | |
| | | 1429 | |
| | | 1434 | |
| | | 1439 | |
| | | 1444 | |
| | | 1449 | |
| | | 1454 | |
| | | 1459 | |
| | | 1464 | |
| | | 1469 | |
| | | 1474 | |
| | | 1479 | |
| | | 1484 | |
| | | 1489 | |
| | | 1494 | |
| | | 1499 | |
| | | 1504 | |
| | | 1509 | |
| | | 1514 | |
| | | 1519 | |
| | | 1524 | |
| | | 1529 | |
| | | 1534 | |
| | | 1539 | |
| | | 1544 | |
| | | 1549 | |
| | | 1554 | |
| | | 1559 | |
| | | 1564 | |
| | | 1569 | |
| | | 1574 | |
| | | 1579 | |
| | | 1584 | |
| | | 1589 | |
| | | 1594 | |
| | | 1599 | |
| | | 1604 | |
| | | 1609 | |
| | | 1614 | |
| | | 1619 | |
| | | 1624 | |
| | | 1629 | |
| | | 1634 | |
| | | 1639 | |
| | | 1644 | |
| | | 1649 | |
| | | 1654 | |
| | | 1659 | |
| | | 1664 | |
| | | 1669 | |
| | | 1674 | |
| | | 1679 | |
| | | 1684 | |
| | | 1689 | |
| | | 1694 | |
| | | 1699 | |
| | | 1704 | |
| | | 1709 | |
| | | 1714 | |
| | | 1719 | |
| | | 1724 | |
| | | 1729 | |
| | | 1734 | |
| | | 1739 | |
| | | 1744 | |
| | | 1749 | |
| | | 1754 | |
| | | 1759 | |
| | | 1764 | |
| | | 1769 | |
| | | 1774 | |
| | | 1779 | |
| | | 1784 | |
| | | 1789 | |
| | | 1794 | |
| | | 1799 | |
| | | 1804 | |
| | | 1809 | |
| | | 1814 | |
| | | 1819 | |
| | | 1824 | |
| | | 1829 | |
| | | 1834 | |
| | | 1839 | |
| | | 1844 | |
| | | 1849 | |
| | | 1854 | |
| | | 1859 | |
| | | 1864 | |
| | | 1869 | |
| | | 1874 | |
| | | 1879 | |
| | | 1884 | |
| | | 1889 | |
| | | 1894 | |
| | | 1899 | |
| | | 1904 | |
| | | 1909 | |
| | | 1914 | |
| | | 1919 | |
| | | 1924 | |
| | | 1929 | |
| | | 1934 | |
| | | 1939 | |
| | | 1944 | |
| | | 1949 | |
| | | 1954 | |
| | | 1959 | |
| | | 1964 | |
| | | 1969 | |
| | | 1974 | |
| | | 1979 | |
| | | 1984 | |
| | | 1989 | |
| | | 1994 | |
| | | 1999 | |
| | | 2004 | |
| | | 2009 | |
| | | 2014 | |
| | | 2019 | |
| | | 2024 | |
| | | 2029 | |
| | | 2034 | |
| | | 2039 | |
| | | 2044 | |
| | | 2049 | |
| | | 2054 | |
| | | 2059 | |
| | | 2064 | |
| | | 2069 | |
| | | 2074 | |
| | | 2079 | |
| | | 2084 | |
| | | 2089 | |
| | | 2094 | |
| | | 2099 | |
| | | 2104 | |
| | | 2109 | |
| | | 2114 | |
| | | 2119 | |
| | | 2124 | |
| | | 2129 | |
| | | 2134 | |
| | | 2139 | |
| | | 2144 | |
| | | 2149 | |
| | | 2154 | |
| | | 2159 | |
| | | 2164 | |
| | | 2169 | |
| | | 2174 | |
| | | 2179 | |
| | | 2184 | |
| | | 2189 | |
| | | 2194 | |
| | | 2199 | |
| | | 2204 | |
| | | 2209 | |
| | | 2214 | |
| | | 2219 | |
| | | 2224 | |
| | | 2229 | |
| | | 2234 | |
| | | 2239 | |
| | | 2244 | |
| | | 2249 | |
| | | 2254 | |
| | | 2259 | |
| | | 2264 | |
| | | 2269 | |
| | | 2274 | |
| | | 2279 | |
| | | 2284 | |
| | | 2289 | |
| | | 2294 | |
| | | 2299 | |
| | | 2304 | |
| | | 2309 | |
| | | 2314 | |
| | | 2319 | |
| | | 2324 | |
| | | 2329 | |
| | | 2334 | |
| | | 2339 | |
| | | 2344 | |
| | | 2349 | |
| | | 2354 | |
| | | 2359 | |
| | | 2364 | |
| | | 2369 | |
| | | 2374 | |
| | | 2379 | |
| | | 2384 | |
| | | 2389 | |
| | | 2394 | |
| | | 2399 | |
| | | 2404 | |
| | | 2409 | |
| | | 2414 | |
| | | 2419 | |
| | | 2424 | |
| | | 2429 | |
| | | 2434 | |
| | | 2439 | |
| | | 2444 | |
| | | 2449 | |
| | | 2454 | |
| | | 2459 | |
| | | 2464 | |
| | | 2469 | |
| | | 2474 | |
| | | 2479 | |
| | | 2484 | |
| | | 2489 | |
| | | 2494 | |
| | | 2499 | |
| | | 2504 | |
| | | 2509 | |
| | | 2514 | |
| | | 2519 | |
| | | 2524 | |
| | | 2529 | |
| | | 2534 | |
| | | 2539 | |
| | | 2544 | |
| | | 2549 | |
| | | 2554 | |
| | | 2559 | |
| | | 2564 | |
| | | 2569 | |
| | | 2574 | |
| | | 2579 | |
| | | 2584 | |
| | | 2589 | |
| | | 2594 | |
| | | 2599 | |
| | | 2604 | |
| | | 2609 | |
| | | 2614 | |
| | | 2619 | |
| | | 2624 | |
| | | 2629 | |
| | | 2634 | |
| | | 2639 | |
| | | 2644 | |
| | | 2649 | |
| | | 2654</ | |

Fig. 11.







Fig. 12.


HpaI RBS (trp LEADER) KpnI
 AAC TAGTACGCAAGTTCACGTAAAAAGGGTATCGACAATGGTAC
 TTGATCATGCGTTCAAGTGCATTTTCCCATAGCTGTTACC



CONSTRUCTION OF pICI0020

Fig.12 cont.

Fig.13.






Fig. 14.





Fig.14 cont.

CONSTRUCTION OF pIC1102

Fig.15.







Fig.17.



*Fig.18.*PARTIAL SEQUENCE OF pICI1102

Trp Promoter
 TTCTGGCAAATATTCTGAAATGAGCTGTTGACAATTAATCATCGAACTAGTTAACTAGTA

1 -----+-----+-----+-----+-----+-----+ 60

S-D rbs Met KpnI BamHI
 CGCAAGTTCACGTAAAAAGGGTATCGACAATGGTACCCGGGGATCCACCTCAGGGTGGTC

61 -----+-----+-----+-----+-----+-----+ 120

Stop KpnI ----Ricin A----->
 TTTACATTAGAGGATAACAACATGGTACCCAAACAATACCCAATTATAAACTTTACCAC

121 -----+-----+-----+-----+-----+-----+ 180

M V P K Q Y P I I N F T T

AGCGGGTGCCACTGTGCAAAGCTACACAACTTTATCAGAGCTGTTGCGGGTCGTTTAAAC

181 -----+-----+-----+-----+-----+-----+ 240

A G A T V Q S Y T N F I R A V R G R L T

AACTGGAGCTGATGTGAGACATGAAATACCAAGTGTGCCAAACAGAGTTGGTTGCCTAT

241 -----+-----+-----+-----+-----+-----+ 300

T G A D V R H E I P V L P N R V G L P I

AAACCAACGGTTTATTTTAGTTGAACTCTCAAATCATGCAGAGCTTTCTGTTACATTAGC

301 -----+-----+-----+-----+-----+-----+ 360

N Q R F I L V E L S N H A E L S V T L A

CCTGGATGTCACCAATGCATATGTGGTCGGCTACCGTGCTGGAAATAGCGCATATTTCTT

361 -----+-----+-----+-----+-----+-----+ 420

L D V T N A Y V V G Y R A G N S A Y F F

TCATCCTGACAATCAGGAAGATGCAGAAGCAATCACTCATCTTTTCACTGATGTTCAAAA

421 -----+-----+-----+-----+-----+-----+ 480

H P D N Q E D A E A I T H L F T D V Q N

TCGATATACATTGCGCTTTGGTGGTAATTATGATAGACTTGAACAACTTGCTGGTAATCT

481 -----+-----+-----+-----+-----+-----+ 540

R Y T F A F G G N Y D R L E Q L A G N L

GAGAGAAAATATCGAGTTGGGAAATGGTCCACTAGAGGAGGCTATCTCAGCGCTTTATTA

541 -----+-----+-----+-----+-----+-----+ 600

R E N I E L G N G P L E E A I S A L Y Y

TTACAGTACTGGTGGCACTCAGCTTCCAACCTCTGGCTCGTTCCTTTATAATTTGCATCCA

601 -----+-----+-----+-----+-----+-----+ 660

Y S T G G T Q L P T L A R S F I I C I Q

Fig.18(cont.)

661 AATGATTTTCAGAAGCAGCAAGATTCCAATATATTGAGGGAGAAATGCGCACGAGAATTAG
 -----+-----+-----+-----+-----+-----+ 720
 M I S E A A R F Q Y I E G E M R T R I R

721 GTACAACCGGAGATCTGCACCAGATCCTAGCGTAATTACACTTGAGAATAGTTGGGGGAG
 -----+-----+-----+-----+-----+-----+ 780
 Y N R R S A P D P S V I T L E N S W G R

781 ACTTTCCACTGCAATTCAAGAGTCTAACCAAGGAGCCTTTGCTAGTCCAATTCAACTGCA
 -----+-----+-----+-----+-----+-----+ 840
 L S T A I Q E S N Q G A F A S P I Q L Q

841 AAGACGTAATGGTTCCAAATTCAGTGTGTACGATGTGAGTATATTAATCCCTATCATAGC
 -----+-----+-----+-----+-----+-----+ 900
 R R N G S K F S V Y D V S I L I P I I A

901 TCTCATGGTGTATAGATGCGCACCTCCACCATCGTCACAGTTTTGATTGCTTATAAGGCC
 -----+-----+-----+-----+-----+-----+ 960
 L M V Y R C A P P P S S Q F *

KpnI XbaI PstI SphI HindIII
 961 AGTGGTACCGGGGATCCTCTAGAGTCGACCTGCAGGCATGCAAGCTTAGCCCGCCTAAT
 -----+-----+-----+-----+-----+-----+1020

Terminator
 1021 GAGCGGGCTTTTTTTTATCGACCGATGCCCTTGAGAGCCTTCAACCCAGTCAGCTCCTTC
 -----+-----+-----+-----+-----+-----+1080

1081 CGGTGGGCGCGGGGCATGACTATCGTCGCCGCACTTATGACTGTCTTCTTTATCATGCAA
 -----+-----+-----+-----+-----+-----+1140




Fig.19.

THIS PAGE BLANK (USPTO,